# Dan M Roden

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5411767/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 662 papers | 65,722 citations | 640 123 h-index | 1152 229 g-index |
| 693 all docs | 693 docs citations | 693 times ranked | 57080 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | The mutational constraint spectrum quantified from variation in 141,456 humans. Nature, 2020, 581, 434-443. | 13.7 | 6,140 |
| 2 | Drug-Induced Prolongation of the QT Interval. New England Journal of Medicine, 2004, 350, 1013-1022. | 13.9 | 1,800 |
| 3 | Fulminant Myocarditis with Combination Immune Checkpoint Blockade. New England Journal of Medicine, 2016, 375, 1749-1755. | 13.9 | 1,668 |
| 4 | ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. Journal of the American College of Cardiology, 2006, 48, e247-e346. | 1.2 | 1,280 |
| 5 | Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program. Nature, 2021, 590, 290-299. | 13.7 | 1,069 |
| 6 | ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. Circulation, 2006, 114, e385-484. | 1.6 | 1,031 |
| 7 | PheWAS: demonstrating the feasibility of a phenome-wide scan to discover geneâ€“disease associations. Bioinformatics, 2010, 26, 1205-1210. | 1.8 | 966 |
| 8 | Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data. Nature Biotechnology, 2013, 31, 1102-1111. | 9.4 | 846 |
| 9 | Development of a Large-Scale De-Identified DNA Biobank to Enable Personalized Medicine. Clinical Pharmacology and Therapeutics, 2008, 84, 362-369. | 2.3 | 816 |
| 10 | Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncology, The, 2018, 19, 1579-1589. | 5.1 | 742 |
| 11 | Taking the "Idio" out of "Idiosyncratic": Predicting Torsades de Pointes. PACE - Pacing and Clinical Electrophysiology, 1998, 21, 1029-1034. | 0.5 | 623 |
| 12 | The eMERGE Network: A consortium of biorepositories linked to electronic medical records data for conducting genomic studies. BMC Medical Genomics, 2011, 4, 13. | 0.7 | 618 |
| 13 | The Electronic Medical Records and Genomics (eMERGE) Network: past, present, and future. Genetics in Medicine, 2013, 15, 761-771. | 1.1 | 611 |
| 14 | Prevention of Torsade de Pointes in Hospital Settings. Circulation, 2010, 121, 1047-1060. | 1.6 | 567 |
| 15 | Multi-ethnic genome-wide association study for atrial fibrillation. Nature Genetics, 2018, 50, 1225-1233. | 9.4 | 552 |
| 16 | ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias) Tj ETQq0 0 0 rgBT /Overlock 10 T | 0.7 | 546 |
| 17 | Rhythm Association and the Heart R. Europace, 2006, 8, 746-837.<br>Multiple Mechanisms in the Long-QT Syndrome. Circulation, 1996, 94, 1996-2012. | 1.6 | 543 |
| 18 | Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nature Medicine, 2009, 15, 380-383. | 15.2 | 539 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Meta-analysis identifies six new susceptibility loci for atrial fibrillation. Nature Genetics, 2012, 44, 670-675. | 9.4 | 533 |
| 20 | Genetic Determinants of Response to Warfarin during Initial Anticoagulation. New England Journal of Medicine, 2008, 358, 999-1008. | 13.9 | 516 |
| 21 | Allelic Variants in Long-QT Disease Genes in Patients With Drug-Associated Torsades de Pointes. Circulation, 2002, 105, 1943-1948. | 1.6 | 514 |
| 22 | Incidence and clinical features of the quinidine-associated long QT syndrome: Implications for patient care. American Heart Journal, 1986, 111, 1088-1093. | 1.2 | 498 |
| 23 | Implementing genomic medicine in the clinic: the future is here. Genetics in Medicine, 2013, 15, 258-267. | 1.1 | 472 |
| 24 | Exome-wide association study of plasma lipids in >300,000 individuals. Nature Genetics, 2017, 49, 1758-1766. | 9.4 | 470 |
| 25 | Common variants at SCN5A-SCN10A and HEY2 are associated with Brugada syndrome, a rare disease with high risk of sudden cardiac death. Nature Genetics, 2013, 45, 1044-1049. | 9.4 | 467 |
| 26 | ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death--executive summary: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients with) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 | 10 | 454 |
| 27 | with the European Heart Rhythm Associat. European Heart Journal, 2006, 27, 2099-2140. Common variants in KCNN3 are associated with lone atrial fibrillation. Nature Genetics, 2010, 42, 240-244. | 9.4 | 438 |
| 28 | A sequence variant in ZFHX3 on 16q22 associates with atrial fibrillation and ischemic stroke. Nature Genetics, 2009, 41, 876-878. | 9.4 | 434 |
| 29 | Coding Variation inANGPTL4,LPL,andSVEP1and the Risk of Coronary Disease. New England Journal of Medicine, 2016, 374, 1134-1144. | 13.9 | 427 |
| 30 | A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood, 2008, 112, 1022-1027. | 0.6 | 410 |
| 31 | Inhibition of P-Glycoproteinâ€“Mediated Drug Transport. Circulation, 1999, 99, 552-557. | 1.6 | 407 |
| 32 | Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharmaceutical Research, 1999, 16, 408-414. | 1.7 | 404 |
| 33 | Sodium channel Î²1 subunit mutations associated with Brugada syndrome and cardiac conduction disease in humans. Journal of Clinical Investigation, 2008, 118, 2260-8. | 3.9 | 400 |
| 34 | Long-QT Syndrome. New England Journal of Medicine, 2008, 358, 169-176. | 13.9 | 387 |
| 35 | Inactivating Mutations in NPC1L1 and Protection from Coronary Heart Disease. New England Journal of Medicine, 2014, 371, 2072-2082. | 13.9 | 386 |
| 36 | Metabolic Syndrome and Risk of Development of Atrial Fibrillation. Circulation, 2008, 117, 1255-1260. | 1.6 | 378 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Inherited causes of clonal haematopoiesis in 97,691 whole genomes. Nature, 2020, 586, 763-768. | 13.7 | 376 |
| 38 | Casq2 deletion causes sarcoplasmic reticulum volume increase, premature Ca2+ release, and catecholaminergic polymorphic ventricular tachycardia. Journal of Clinical Investigation, 2006, 116, 2510-20. | 3.9 | 375 |
| 39 | Drug-Induced Long QT Syndrome. Pharmacological Reviews, 2010, 62, 760-781. | 7.1 | 374 |
| 40 | Operational Implementation of Prospective Genotyping for Personalized Medicine: The Design of the Vanderbilt PREDICT Project. Clinical Pharmacology and Therapeutics, 2012, 92, 87-95. | 2.3 | 370 |
| 41 | Extracellular Potassium Modulation of Drug Block of I <sub>Kr</sub>. Circulation, 1996, 93, 407-411. | 1.6 | 367 |
| 42 | Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nature Reviews Drug Discovery, 2007, 6, 904-916. | 21.5 | 351 |
| 43 | Drugs and Brugada syndrome patients: Review of the literature, recommendations, and an up-to-date website (www.brugadadrugs.org). Heart Rhythm, 2009, 6, 1335-1341. | 0.3 | 342 |
| 44 | Return of Genomic Results to Research Participants: The Floor, the Ceiling, and the Choices In Between. American Journal of Human Genetics, 2014, 94, 818-826. | 2.6 | 342 |
| 45 | Incorporation of Pharmacogenomics into Routine Clinical Practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline Development Process. Current Drug Metabolism, 2014, 15, 209-217. | 0.7 | 341 |
| 46 | Prevention of Torsade de Pointes in Hospital Settings. Journal of the American College of Cardiology, 2010, 55, 934-947. | 1.2 | 316 |
| 47 | Drug-Induced Torsades de Pointes and Implications for Drug Development. Journal of Cardiovascular Electrophysiology, 2004, 15, 475-495. | 0.8 | 314 |
| 48 | Robust Replication of Genotype-Phenotype Associations across Multiple Diseases in an Electronic Medical Record. American Journal of Human Genetics, 2010, 86, 560-572. | 2.6 | 302 |
| 49 | The long QT syndromes: genetic basis and clinical implications. Journal of the American College of Cardiology, 2000, 36, 1-12. | 1.2 | 300 |
| 50 | Transgenic Mice Overexpressing MutantPRKAG2Define the Cause of Wolff-Parkinson-White Syndrome in Glycogen Storage Cardiomyopathy. Circulation, 2003, 107, 2850-2856. | 1.6 | 300 |
| 51 | PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study. Lancet Diabetes and Endocrinology,the, 2017, 5, 97-105. | 5.5 | 298 |
| 52 | Genetic and Molecular Basis of Cardiac Arrhythmias: Impact on Clinical Management Parts I and II. Circulation, 1999, 99, 518-528. | 1.6 | 295 |
| 53 | Cardiac Sodium Channel ( SCN5A ) Variants Associated with Atrial Fibrillation. Circulation, 2008, 117, 1927-1935. | 1.6 | 292 |
| 54 | PheKB: a catalog and workflow for creating electronic phenotype algorithms for transportability. Journal of the American Medical Informatics Association: JAMIA, 2016, 23, 1046-1052. | 2.2 | 284 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Genetic association study of QT interval highlights role for calcium signaling pathways in myocardial repolarization. Nature Genetics, 2014, 46, 826-836. | 9.4 | 281 |
| 56 | Large-scale analyses of common and rare variants identify 12 new loci associated with atrial fibrillation. Nature Genetics, 2017, 49, 946-952. | 9.4 | 279 |
| 57 | Close bidirectional relationship between chronic kidney disease and atrial fibrillation: The Niigata preventive medicine study. American Heart Journal, 2009, 158, 629-636. | 1.2 | 276 |
| 58 | A rare variant in MYH6 is associated with high risk of sick sinus syndrome. Nature Genetics, 2011, 43, 316-320. | 9.4 | 275 |
| 59 | The phenotypic legacy of admixture between modern humans and Neandertals. Science, 2016, 351, 737-741. | 6.0 | 269 |
| 60 | Evaluating phecodes, clinical classification software, and ICD-9-CM codes for phenome-wide association studies in the electronic health record. PLoS ONE, 2017, 12, e0175508. | 1.1 | 268 |
| 61 | Pharmacogenomics. Lancet, The, 2019, 394, 521-532. | 6.3 | 261 |
| 62 | Cardiac Ion Channels. Annual Review of Physiology, 2002, 64, 431-475. | 5.6 | 259 |
| 63 | When good drugs go bad. Nature, 2007, 446, 975-977. | 13.7 | 246 |
| 64 | Molecular cloning and characterization of two voltageâ€gated K <sup>+</sup> channel cDNAs from human ventricle. FASEB Journal, 1991, 5, 331-337. | 0.2 | 242 |
| 65 | Calmodulin Kinase II and Arrhythmias in a Mouse Model of Cardiac Hypertrophy. Circulation, 2002, 106, 1288-1293. | 1.6 | 240 |
| 66 | Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet, The, 2013, 382, 790-796. | 6.3 | 237 |
| 67 | Predictive Accuracy of a Polygenic Risk Score Compared With a Clinical Risk Score for Incident Coronary Heart Disease. JAMA - Journal of the American Medical Association, 2020, 323, 627. | 3.8 | 234 |
| 68 | The genetic basis of variability in drug responses. Nature Reviews Drug Discovery, 2002, 1, 37-44. | 21.5 | 233 |
| 69 | Variants Near FOXE1 Are Associated with Hypothyroidism and Other Thyroid Conditions: Using Electronic Medical Records for Genome- and Phenome-wide Studies. American Journal of Human Genetics, 2011, 89, 529-542. | 2.6 | 232 |
| 70 | KCNH2 -K897T Is a Genetic Modifier of Latent Congenital Long-QT Syndrome. Circulation, 2005, 112, 1251-1258. | 1.6 | 228 |
| 71 | Pharmacogenomics: Challenges and Opportunities. Annals of Internal Medicine, 2006, 145, 749. | 2.0 | 228 |
| 72 | Classification of deaths after myocardial infarction as arrhythmic or nonarrhythmic (The Cardiac) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 6 | 0.7 | 227 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Nkx2-5 mutation causes anatomic hypoplasia of the cardiac conduction system. Journal of Clinical Investigation, 2004, 113, 1130-1137. | 3.9 | 217 |
| 74 | A calcium sensor in the sodium channel modulates cardiac excitability. Nature, 2002, 415, 442-447. | 13.7 | 216 |
| 75 | Common Sodium Channel Promoter Haplotype in Asian Subjects Underlies Variability in Cardiac Conduction. Circulation, 2006, 113, 338-344. | 1.6 | 215 |
| 76 | Systematic Evaluation of Pleiotropy Identifies 6 Further Loci Associated WithÂCoronary ArteryÂDisease. Journal of the American College of Cardiology, 2017, 69, 823-836. | 1.2 | 214 |
| 77 | Mutations in Sodium Channel Î²1- and Î²2-Subunits Associated With Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2009, 2, 268-275. | 2.1 | 212 |
| 78 | Genetics of acquired long QT syndrome. Journal of Clinical Investigation, 2005, 115, 2025-2032. | 3.9 | 210 |
| 79 | Drug-induced long QT and torsade de pointes: recent advances. Current Opinion in Cardiology, 2007, 22, 39-43. | 0.8 | 195 |
| 80 | Large scale replication and meta-analysis of variants on chromosome 4q25 associated with atrial fibrillation. European Heart Journal, 2008, 30, 813-819. | 1.0 | 193 |
| 81 | Phenome-Wide Association Studies as a Tool to Advance Precision Medicine. Annual Review of Genomics and Human Genetics, 2016, 17, 353-373. | 2.5 | 193 |
| 82 | Total Suppression of Ventricular Arrhythmias by Encainide. New England Journal of Medicine, 1980, 302, 877-882. | 13.9 | 189 |
| 83 | Principles of Human Subjects Protections Applied in an Optâ€Out, Deâ€identified Biobank. Clinical and Translational Science, 2010, 3, 42-48. | 1.5 | 185 |
| 84 | The E1784K mutation in SCN5A is associated with mixed clinical phenotype of type 3 long QT syndrome. Journal of Clinical Investigation, 2008, 118, 2219-29. | 3.9 | 184 |
| 85 | Replacement by Homologous Recombination of the minK Gene With lacZ Reveals Restriction of minK Expression to the Mouse Cardiac Conduction System. Circulation Research, 1999, 84, 146-152. | 2.0 | 179 |
| 86 | Phenotypic Variability and Unusual Clinical Severity of Congenital Long-QT Syndrome in a Founder Population. Circulation, 2005, 112, 2602-2610. | 1.6 | 179 |
| 87 | Validating drug repurposing signals using electronic health records: a case study of metformin associated with reduced cancer mortality. Journal of the American Medical Informatics Association: JAMIA, 2015, 22, 179-191. | 2.2 | 178 |
| 88 | Flecainide. New England Journal of Medicine, 1986, 315, 36-41. | 13.9 | 172 |
| 89 | Mice with the R176Q cardiac ryanodine receptor mutation exhibit catecholamine-induced ventricular tachycardia and cardiomyopathy. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 12179-12184. | 3.3 | 172 |
| 90 | Drug Block of I Kr : Model Systems and Relevance to Human Arrhythmias. Journal of Cardiovascular Pharmacology, 2001, 38, 737-744. | 0.8 | 171 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Genome-wide association study identifies a susceptibility locus at 21q21 for ventricular fibrillation in acute myocardial infarction. Nature Genetics, 2010, 42, 688-691. | 9.4 | 170 |
| 92 | Cardiovascular Toxicities AssociatedÂWith Ibrutinib. Journal of the American College of Cardiology, 2019, 74, 1667-1678. | 1.2 | 169 |
| 93 | Genome- and Phenome-Wide Analyses of Cardiac Conduction Identifies Markers of Arrhythmia Risk. Circulation, 2013, 127, 1377-1385. | 1.6 | 167 |
| 94 | Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update. Clinical Pharmacology and Therapeutics, 2022, 112, 959-967. | 2.3 | 166 |
| 95 | Suppression of resistant ventricular arrhythmias by twice daily dosing with flecainide. American Journal of Cardiology, 1981, 48, 1133-1140. | 0.7 | 164 |
| 96 | The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Overcoming Challenges of Real-World Implementation. Clinical Pharmacology and Therapeutics, 2013, 94, 207-210. | 2.3 | 164 |
| 97 | Phenotype risk scores identify patients with unrecognized Mendelian disease patterns. Science, 2018, 359, 1233-1239. | 6.0 | 164 |
| 98 | Blocking Scn10a Channels in Heart Reduces Late Sodium Current and Is Antiarrhythmic. Circulation Research, 2012, 111, 322-332. | 2.0 | 163 |
| 99 | Normalization of Acquired QT Prolongation in Humans by Intravenous Potassium. Circulation, 1997, 96, 2149-2154. | 1.6 | 163 |
| 100 | Pharmacogenomics. Circulation, 2011, 123, 1661-1670. | 1.6 | 162 |
| 101 | Defining the Cellular Phenotype of â€œAnkyrin-B Syndromeâ€•Variants. Circulation, 2007, 115, 432-441. | 1.6 | 161 |
| 102 | Ibutilide, a Methanesulfonanilide Antiarrhythmic, Is a Potent Blocker of the Rapidly Activating Delayed Rectifier K <sup>+</sup> Current (I <sub>Kr</sub> ) in AT-1 Cells. Circulation, 1995, 91, 1799-1806. | 1.6 | 158 |
| 103 | Antiarrhythmic efficacy, pharmacokinetics and safety of N-acetylprocainamide in human subjects: Comparison with procainamide. American Journal of Cardiology, 1980, 46, 463-468. | 0.7 | 157 |
| 104 | Assessing the contribution of rare variants to complex trait heritability from whole-genome sequence data. Nature Genetics, 2022, 54, 263-273. | 9.4 | 156 |
| 105 | ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Deathâ€”Executive Summary. Journal of the American College of Cardiology, 2006, 48, 1064-1108. | 1.2 | 154 |
| 106 | Cardiac-specific overexpression of AT1 receptor mutant lacking GÂq/GÂi coupling causes hypertrophy and bradycardia in transgenic mice. Journal of Clinical Investigation, 2005, 115, 3045-3056. | 3.9 | 153 |
| 107 | A Large Candidate Gene Survey Identifies the KCNE1 D85N Polymorphism as a Possible Modulator of Drug-Induced Torsades de Pointes. Circulation: Cardiovascular Genetics, 2012, 5, 91-99. | 5.1 | 150 |
| 108 | Prospective, population-based long QT molecular autopsy study of postmortem negative sudden death in 1 to 40 year olds. Heart Rhythm, 2011, 8, 412-419. | 0.3 | 148 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Association of Arrhythmia-Related Genetic Variants With Phenotypes Documented in Electronic Medical Records. JAMA - Journal of the American Medical Association, 2016, 315, 47. | 3.8 | 148 |
| 110 | Global implementation of genomic medicine: We are not alone. Science Translational Medicine, 2015, 7, 290ps13. | 5.8 | 146 |
| 111 | Rapid Inactivation Determines the Rectification and [K <sup>+</sup> ] <sub>o</sub> Dependence of the Rapid Component of the Delayed Rectifier K <sup>+</sup> Current in Cardiac Cells. Circulation Research, 1997, 80, 782-789. | 2.0 | 146 |
| 112 | The Role of Genetically Determined Polymorphic Drug Metabolism in the Beta-Blockade Produced by Propafenone. New England Journal of Medicine, 1990, 322, 1764-1768. | 13.9 | 144 |
| 113 | Relation of the Severity of Obstructive Sleep Apnea in Response to Anti-Arrhythmic Drugs in Patients With Atrial Fibrillation or Atrial Flutter. American Journal of Cardiology, 2012, 110, 369-372. | 0.7 | 144 |
| 114 | Genome-wide association studies in pharmacogenomics. Pharmacogenetics and Genomics, 2013, 23, 383-394. | 0.7 | 144 |
| 115 | Screening for Acute I <sub>Kr</sub> Block Is Insufficient to Detect Torsades de Pointes Liability. Circulation, 2014, 130, 224-234. | 1.6 | 144 |
| 116 | Predicting drugâ€induced QT prolongation and torsades de pointes. Journal of Physiology, 2016, 594, 2459-2468. | 1.3 | 144 |
| 117 | Association Between Titin Loss-of-Function Variants and Early-Onset Atrial Fibrillation. JAMA - Journal of the American Medical Association, 2018, 320, 2354. | 3.8 | 144 |
| 118 | Congenital Long-QT Syndrome Caused by a Novel Mutation in a Conserved Acidic Domain of the Cardiac Na <sup>+</sup> Channel. Circulation, 1999, 99, 3165-3171. | 1.6 | 143 |
| 119 | Cardiac repolarization: Current knowledge, critical gaps, and new approaches to drug development and patient management. American Heart Journal, 2002, 144, 769-781. | 1.2 | 143 |
| 120 | The cardiac arrhythmia suppression trial: First CAST â€¦ then CAST-II. Journal of the American College of Cardiology, 1992, 19, 894-898. | 1.2 | 140 |
| 121 | Striking In Vivo Phenotype of a Disease-Associated Human SCN5A Mutation Producing Minimal Changes in Vitro. Circulation, 2011, 124, 1001-1011. | 1.6 | 137 |
| 122 | Considerations for Drug Interactions on QTc in Exploratory COVID-19 Treatment. Circulation, 2020, 141, e906-e907. | 1.6 | 137 |
| 123 | Propafenone. New England Journal of Medicine, 1990, 322, 518-525. | 13.9 | 136 |
| 124 | Inherited Long QT Syndromes:.. Journal of Cardiovascular Electrophysiology, 1999, 10, 1664-1683. | 0.8 | 136 |
| 125 | A genome- and phenome-wide association study to identify genetic variants influencing platelet count and volume and their pleiotropic effects. Human Genetics, 2014, 133, 95-109. | 1.8 | 135 |
| 126 | A K+ Channel Splice Variant Common in Human Heart Lacks a C-terminal Domain Required for Expression of Rapidly Activating Delayed Rectifier Current. Journal of Biological Chemistry, 1998, 273, 27231-27235. | 1.6 | 132 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Efficacy of Flecainide in the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia. JAMA Cardiology, 2017, 2, 759. | 3.0 | 127 |
| 128 | Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis. Lancet Respiratory Medicine,the, 2019, 7, 227-238. | 5.2 | 122 |
| 129 | The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statinâ€Associated Musculoskeletal Symptoms. Clinical Pharmacology and Therapeutics, 2022, 111, 1007-1021. | 2.3 | 120 |
| 130 | Symptomatic Response to Antiarrhythmic Drug Therapy Is Modulated by a Common Single Nucleotide Polymorphism in Atrial Fibrillation. Journal of the American College of Cardiology, 2012, 60, 539-545. | 1.2 | 118 |
| 131 | Biobanks and Electronic Medical Records: Enabling Cost-Effective Research. Science Translational Medicine, 2014, 6, 234cm3. | 5.8 | 118 |
| 132 | Risks and Benefits of Antiarrhythmic Therapy. New England Journal of Medicine, 1994, 331, 785-791. | 13.9 | 117 |
| 133 | Identification of Genomic Predictors of Atrioventricular Conduction. Circulation, 2010, 122, 2016-2021. | 1.6 | 117 |
| 134 | Cellular basis of drugâ€induced torsades de pointes. British Journal of Pharmacology, 2008, 154, 1502-1507. | 2.7 | 113 |
| 135 | Mechanisms and management of proarrhythmia. American Journal of Cardiology, 1998, 82, 49I-57I. | 0.7 | 111 |
| 136 | Desiderata for computable representations of electronic health records-driven phenotype algorithms. Journal of the American Medical Informatics Association: JAMIA, 2015, 22, 1220-1230. | 2.2 | 110 |
| 137 | Research Directions in the Clinical Implementation of Pharmacogenomics: An Overview of US Programs and Projects. Clinical Pharmacology and Therapeutics, 2018, 103, 778-786. | 2.3 | 110 |
| 138 | Calmodulin Kinase Inhibition Prevents Development of the Arrhythmogenic Transient Inward Current. Circulation Research, 1999, 84, 906-912. | 2.0 | 109 |
| 139 | Phenotypic Refinement of Heart Failure in a National Biobank Facilitates Genetic Discovery. Circulation, 2019, 139, 489-501. | 1.6 | 109 |
| 140 | Role of common and rare variants in SCN10A: results from the Brugada syndrome QRS locus gene discovery collaborative study. Cardiovascular Research, 2015, 106, 520-529. | 1.8 | 108 |
| 141 | Drug-Sensitized Zebrafish Screen Identifies Multiple Genes, Including GINS3 , as Regulators of Myocardial Repolarization. Circulation, 2009, 120, 553-559. | 1.6 | 106 |
| 142 | Repolarization Reserve. Circulation, 2008, 118, 981-982. | 1.6 | 105 |
| 143 | Phenome-wide scanning identifies multiple diseases and disease severity phenotypes associated with HLA variants. Science Translational Medicine, 2017, 9, . | 5.8 | 105 |
| 144 | Torsade de pointes. Clinical Cardiology, 1993, 16, 683-686. | 0.7 | 104 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | Variation in the 4q25 Chromosomal Locus Predicts Atrial Fibrillation After Coronary Artery Bypass Graft Surgery. Circulation: Cardiovascular Genetics, 2009, 2, 499-506. | 5.1 | 104 |
| 146 | Differential expression of KvLQT1 and its regulator IsK in mouse epithelia. American Journal of Physiology - Cell Physiology, 2001, 280, C359-C372. | 2.1 | 103 |
| 147 | A KCNJ8 mutation associated with early repolarization and atrial fibrillation. Europace, 2012, 14, 1428-1432. | 0.7 | 103 |
| 148 | Bedside Back to Bench: Building Bridges between Basic and Clinical Genomic Research. Cell, 2017, 169, 6-12. | 13.5 | 103 |
| 149 | Genetics of glucocorticoid-associated osteonecrosis in children with acute lymphoblastic leukemia. Blood, 2015, 126, 1770-1776. | 0.6 | 102 |
| 150 | Common Variation in the NOS1AP Gene Is Associated With Drug-Induced QT Prolongation and Ventricular Arrhythmia. Journal of the American College of Cardiology, 2012, 60, 841-850. | 1.2 | 101 |
| 151 | Anticancer drug-induced cardiac rhythm disorders: Current knowledge and basic underlying mechanisms. , 2018, 189, 89-103. | | 101 |
| 152 | Concentration-dependent pharmacologic properties of sotalol. American Journal of Cardiology, 1986, 57, 1160-1165. | 0.7 | 99 |
| 153 | Harmonizing Clinical Sequencing and Interpretation for the eMERGE III Network. American Journal of Human Genetics, 2019, 105, 588-605. | 2.6 | 99 |
| 154 | Unusual Effects of a QT-Prolonging Drug, Arsenic Trioxide, on Cardiac Potassium Currents. Circulation, 2004, 109, 26-29. | 1.6 | 98 |
| 155 | Common Genetic Variants and Response to Atrial Fibrillation Ablation. Circulation: Arrhythmia and Electrophysiology, 2015, 8, 296-302. | 2.1 | 98 |
| 156 | A practical approach to torsade de pointes. Clinical Cardiology, 1997, 20, 285-290. | 0.7 | 97 |
| 157 | Protecting the Heart Against Arrhythmias: Potassium Current Physiology and Repolarization Reserve. Circulation, 2005, 112, 1376-1378. | 1.6 | 97 |
| 158 | Performant Mutation Identification Using Targeted Next-Generation Sequencing of 14 Thoracic Aortic Aneurysm Genes. Human Mutation, 2015, 36, 808-814. | 1.1 | 97 |
| 159 | Unmasking of Brugada Syndrome by Lithium. Circulation, 2005, 112, 1527-1531. | 1.6 | 96 |
| 160 | Common Genetic Variant Risk Score Is Associated With Drug-Induced QT Prolongation and Torsade de Pointes Risk. Circulation, 2017, 135, 1300-1310. | 1.6 | 96 |
| 161 | Cardiac potassium channel dysfunction in sudden infant death syndrome. Journal of Molecular and Cellular Cardiology, 2008, 44, 571-581. | 0.9 | 95 |
| 162 | Assessing the accuracy of observer-reported ancestry in a biorepository linked to electronic medical records. Genetics in Medicine, 2010, 12, 648-650. | 1.1 | 94 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | Polymorphism modulates symptomatic response to antiarrhythmic drug therapy in patients with lone atrial fibrillation. Heart Rhythm, 2007, 4, 743-749. | 0.3 | 92 |
| 164 | Acquired Long QT Syndromes and the Risk of Proarrhythmia. Journal of Cardiovascular Electrophysiology, 2000, 11, 938-940. | 0.8 | 90 |
| 165 | Predicting warfarin dosage in Europeanâ€“Americans and Africanâ€“Americans using DNA samples linked to an electronic health record. Pharmacogenomics, 2012, 13, 407-418. | 0.6 | 90 |
| 166 | Systemic Administration of Calmodulin Antagonist W-7 or Protein Kinase A Inhibitor H-8 Prevents Torsade de Pointes in Rabbits. Circulation, 1999, 100, 2437-2442. | 1.6 | 89 |
| 167 | Cardiovascular Toxicities Associated With Hydroxychloroquine and Azithromycin. Circulation, 2020, 142, 303-305. | 1.6 | 89 |
| 168 | High-Throughput Reclassification of SCN5A Variants. American Journal of Human Genetics, 2020, 107, 111-123. | 2.6 | 88 |
| 169 | Electronic health record design and implementation for pharmacogenomics: a local perspective. Genetics in Medicine, 2013, 15, 833-841. | 1.1 | 87 |
| 170 | Genetic Risk Prediction of Atrial Fibrillation. Circulation, 2017, 135, 1311-1320. | 1.6 | 87 |
| 171 | Cisapride-Induced Torsades de Pointes. Journal of Cardiovascular Electrophysiology, 1998, 9, 1109-1113. | 0.8 | 86 |
| 172 | Exaggerated QT prolongation after cardioversion of atrial fibrillation. Journal of the American College of Cardiology, 1999, 34, 396-401. | 1.2 | 86 |
| 173 | Gating-Dependent Mechanisms for Flecainide Action in SCN5A -Linked Arrhythmia Syndromes. Circulation, 2001, 104, 1200-1205. | 1.6 | 85 |
| 174 | Augmented potassium current is a shared phenotype for two genetic defects associated with familial atrial fibrillation. Journal of Molecular and Cellular Cardiology, 2010, 48, 181-190. | 0.9 | 85 |
| 175 | Defective Human Ether-Ã-go-go-related Gene Trafficking Linked to an Endoplasmic Reticulum Retention Signal in the C Terminus. Journal of Biological Chemistry, 2002, 277, 27442-27448. | 1.6 | 84 |
| 176 | A Common Î²1-Adrenergic Receptor Polymorphism Predicts Favorable Response to Rate-Control Therapy in Atrial Fibrillation. Journal of the American College of Cardiology, 2012, 59, 49-56. | 1.2 | 84 |
| 177 | Transethnic Genome-Wide Association Study Provides Insights in the Genetic Architecture and Heritability of Long QT Syndrome. Circulation, 2020, 142, 324-338. | 1.6 | 83 |
| 178 | Amiodarone dosing: A proposal based on its pharmacokinetics. American Heart Journal, 1983, 106, 951-956. | 1.2 | 82 |
| 179 | Clinical features and basic mechanisms of quinidine-induced arrhythmias. Journal of the American College of Cardiology, 1986, 8, 73A-78A. | 1.2 | 82 |
| 180 | Common genetic polymorphism at 4q25 locus predicts atrial fibrillation recurrence after successful cardioversion. Heart Rhythm, 2013, 10, 849-855. | 0.3 | 82 |

| # | Article | IF | Citations |
|---|---|---|---|
| 181 | Genomic medicine for undiagnosed diseases. Lancet, The, 2019, 394, 533-540. | 6.3 | 82 |
| 182 | Chromosome 4q25 Variants Are Genetic Modifiers of Rare Ion Channel Mutations Associated With Familial Atrial Fibrillation. Journal of the American College of Cardiology, 2012, 60, 1173-1181. | 1.2 | 80 |
| 183 | Calmodulin Inhibitor W-7 Unmasks a Novel Electrocardiographic Parameter That Predicts Initiation of Torsade de Pointes. Circulation, 2002, 105, 770-774. | 1.6 | 79 |
| 184 | Atrial Fibrillation in KCNE1-Null Mice. Circulation Research, 2005, 97, 62-69. | 2.0 | 79 |
| 185 | Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy. Blood, 2009, 113, 3925-3930. | 0.6 | 79 |
| 186 | Common atrial fibrillation risk alleles at 4q25 predict recurrence after catheter-based atrial fibrillation ablation. Heart Rhythm, 2013, 10, 394-400. | 0.3 | 79 |
| 187 | eMERGEing progress in genomicsÃ¢â‚¬â€the first seven years. Frontiers in Genetics, 2014, 5, 184. | 1.1 | 79 |
| 188 | Azithromycin Causes a Novel Proarrhythmic Syndrome. Circulation: Arrhythmia and Electrophysiology, 2017, 10, . | 2.1 | 79 |
| 189 | Modification of Proteins by Isoketal-containing Oxidized Phospholipids. Journal of Biological Chemistry, 2004, 279, 13447-13451. | 1.6 | 78 |
| 190 | Voltage-Gated Sodium Channels Are Required for Heart Development in Zebrafish. Circulation Research, 2010, 106, 1342-1350. | 2.0 | 78 |
| 191 | Benefit of Preemptive Pharmacogenetic Information on Clinical Outcome. Clinical Pharmacology and Therapeutics, 2018, 103, 787-794. | 2.3 | 77 |
| 192 | Genetic susceptibility to acquired long QT syndrome: Pharmacologic challenge in first-degree relatives. Heart Rhythm, 2005, 2, 134-140. | 0.3 | 76 |
| 193 | Genetic mechanisms of atrial fibrillation: impact on response to treatment. Nature Reviews Cardiology, 2013, 10, 317-329. | 6.1 | 76 |
| 194 | Clinical pharmacology of propafenone: Pharmacokinetics, metabolism and concentration-response relations. American Journal of Cardiology, 1984, 54, 9D-12D. | 0.7 | 75 |
| 195 | A genetic framework for improving arrhythmia therapy. Nature, 2008, 451, 929-936. | 13.7 | 74 |
| 196 | Facilitating pharmacogenetic studies using electronic health records and natural-language processing: a case study of warfarin. Journal of the American Medical Informatics Association: JAMIA, 2011, 18, 387-391. | 2.2 | 74 |
| 197 | Genetics and Cardiovascular Disease. Circulation, 2012, 126, 142-157. | 1.6 | 74 |
| 198 | Electrophysiologic Substrate in Congenital Long QT Syndrome. Circulation, 2014, 130, 1936-1943. | 1.6 | 74 |

| # | Article | IF | Citations |
|---|---|---|---|
| 199 | Four Susceptibility Loci for Gallstone Disease Identified in a Meta-analysis of Genome-Wide Association Studies. Gastroenterology, 2016, 151, 351-363.e28. | 0.6 | 74 |
| 200 | Evaluating electronic health record data sources and algorithmic approaches to identify hypertensive individuals. Journal of the American Medical Informatics Association: JAMIA, 2017, 24, 162-171. | 2.2 | 74 |
| 201 | Tocainide. New England Journal of Medicine, 1986, 315, 41-45. | 13.9 | 73 |
| 202 | A Missense Variant in PLEC Increases RiskÂof Atrial Fibrillation. Journal of the American College of Cardiology, 2017, 70, 2157-2168. | 1.2 | 73 |
| 203 | Drug-induced arrhythmia: pharmacogenomic prescribing?. European Heart Journal, 2013, 34, 89-95. | 1.0 | 72 |
| 204 | Classification and Reporting of Potentially Proarrhythmic Common Genetic Variation in Long QT Syndrome Genetic Testing. Circulation, 2018, 137, 619-630. | 1.6 | 72 |
| 205 | Anti-minK Antisense Decreases the Amplitude of the Rapidly Activating Cardiac Delayed Rectifier K <sup>+</sup> Current. Circulation Research, 1995, 77, 1246-1253. | 2.0 | 72 |
| 206 | Cardiovascular Pharmacogenomics. Circulation Research, 2011, 109, 807-820. | 2.0 | 71 |
| 207 | Genetic susceptibility for COVID-19â€“associated sudden cardiac death in African Americans. Heart Rhythm, 2020, 17, 1487-1492. | 0.3 | 71 |
| 208 | Novel KCNA5 mutation implicates tyrosine kinase signaling in human atrial fibrillation. Heart Rhythm, 2010, 7, 1246-1252. | 0.3 | 70 |
| 209 | Exome Sequencing Implicates an Increased Burden of Rare Potassium Channel Variants in the Risk of Drug-Induced Long QT Interval Syndrome. Journal of the American College of Cardiology, 2014, 63, 1430-1437. | 1.2 | 70 |
| 210 | A Structural Requirement for Processing the Cardiac K+ Channel KCNQ1. Journal of Biological Chemistry, 2004, 279, 33976-33983. | 1.6 | 69 |
| 211 | Clopidogrel and the Concept of High-Risk Pharmacokinetics. Circulation, 2009, 119, 2127-2130. | 1.6 | 69 |
| 212 | Pharmacogenomic polygenic response score predicts ischaemic events and cardiovascular mortality in clopidogrel-treated patients. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 203-210. | 1.4 | 69 |
| 213 | Quinidine reduces clearance of (+)-propranolol more than (â^')-propranolol through marked reduction in 4-hydroxylation. Clinical Pharmacology and Therapeutics, 1990, 47, 686-693. | 2.3 | 68 |
| 214 | Co-inheritance of the polymorphic metabolism of encainide and debrisoquin. Clinical Pharmacology and Therapeutics, 1986, 39, 282-287. | 2.3 | 67 |
| 215 | Androgenic Effects on Ventricular Repolarization. Circulation, 2019, 140, 1070-1080. | 1.6 | 67 |
| 216 | Phenome-wide association studies demonstrating pleiotropy of genetic variants within FTO with and without adjustment for body mass index. Frontiers in Genetics, 2014, 5, 250. | 1.1 | 66 |

| # | Article | IF | Citations |
|---|---|---|---|
| 217 | Early-Onset Atrial Fibrillation and the Prevalence of Rare Variants in Cardiomyopathy and Arrhythmia Genes. JAMA Cardiology, 2021, 6, 1371. | 3.0 | 66 |
| 218 | SCN10A/Nav1.8 modulation of peak and late sodium currents in patients with early onset atrial fibrillation. Cardiovascular Research, 2014, 104, 355-363. | 1.8 | 65 |
| 219 | Pharmacological Properties and Functional Role of Kslow Current in Mouse Pancreatic Î²-Cells. Journal of General Physiology, 2005, 126, 353-363. | 0.9 | 64 |
| 220 | Enhancing Literacy in Cardiovascular Genetics: A Scientific Statement From the American Heart Association. Circulation: Cardiovascular Genetics, 2016, 9, 448-467. | 5.1 | 64 |
| 221 | LPA Variants Are Associated With Residual Cardiovascular Risk in Patients Receiving Statins. Circulation, 2018, 138, 1839-1849. | 1.6 | 64 |
| 222 | Assessment of the Relationship Between Genetic Determinants of Thyroid Function and Atrial Fibrillation. JAMA Cardiology, 2019, 4, 144. | 3.0 | 64 |
| 223 | Clinical and Genetic Determinants of Warfarin Pharmacokinetics and Pharmacodynamics during Treatment Initiation. PLoS ONE, 2011, 6, e27808. | 1.1 | 62 |
| 224 | Pause-dependent polymorphic ventricular tachycardia during long-term treatment with dofetilide. Journal of the American College of Cardiology, 2001, 37, 1100-1105. | 1.2 | 61 |
| 225 | Frequency of genomic secondaryÂfindings among 21,915 eMERGE network participants. Genetics in Medicine, 2020, 22, 1470-1477. | 1.1 | 61 |
| 226 | Knowledge-Driven Multi-Locus Analysis Reveals Gene-Gene Interactions Influencing HDL Cholesterol Level in Two Independent EMR-Linked Biobanks. PLoS ONE, 2011, 6, e19586. | 1.1 | 60 |
| 227 | Drug therapy for atrial fibrillation: where do we go from here?. Nature Reviews Drug Discovery, 2005, 4, 899-910. | 21.5 | 59 |
| 228 | Prolonged Signal-Averaged P-Wave Duration as an Intermediate Phenotype for Familial Atrial Fibrillation. Journal of the American College of Cardiology, 2008, 51, 1083-1089. | 1.2 | 59 |
| 229 | Genomic Medicine, Precision Medicine, Personalized Medicine: Whatâ€™s in a Name?. Clinical Pharmacology and Therapeutics, 2013, 94, 169-172. | 2.3 | 59 |
| 230 | Multi-ancestry GWAS of the electrocardiographic PR interval identifies 202 loci underlying cardiac conduction. Nature Communications, 2020, 11, 2542. | 5.8 | 59 |
| 231 | Development of the Cardiac Conduction System as Delineated by minKâ€lacZ. Journal of Cardiovascular Electrophysiology, 2003, 14, 383-391. | 0.8 | 58 |
| 232 | A Connexin40 Mutation Associated With a Malignant Variant of Progressive Familial Heart Block Type I. Circulation: Arrhythmia and Electrophysiology, 2012, 5, 163-172. | 2.1 | 58 |
| 233 | Comparison of HLA allelic imputation programs. PLoS ONE, 2017, 12, e0172444. | 1.1 | 58 |
| 234 | Transcription factor ETV1 is essential for rapid conduction in the heart. Journal of Clinical Investigation, 2016, 126, 4444-4459. | 3.9 | 58 |

| # | Article | IF | Citations |
|---|---|---|---|
| 235 | Mechanism of block of a human cardiac potassium channel by terfenadine racemate and enantiomers. British Journal of Pharmacology, 1995, 115, 267-274. | 2.7 | 57 |
| 236 | Whole Exome Sequencing Identifies a Causal RBM20 Mutation in a Large Pedigree With Familial Dilated Cardiomyopathy. Circulation: Cardiovascular Genetics, 2013, 6, 317-326. | 5.1 | 57 |
| 237 | Hypogonadism as a Reversible Cause of Torsades de Pointes in Men. Circulation, 2018, 138, 110-113. | 1.6 | 57 |
| 238 | Enhancing rare variant interpretation in inherited arrhythmias through quantitative analysis of consortium disease cohorts and population controls. Genetics in Medicine, 2021, 23, 47-58. | 1.1 | 57 |
| 239 | Genome Wide Analysis of Drug-Induced Torsades de Pointes: Lack of Common Variants with Large Effect Sizes. PLoS ONE, 2013, 8, e78511. | 1.1 | 57 |
| 240 | Cloning and initial characterization of the human cardiac sodium channel (SCN5A) promoter. Cardiovascular Research, 2004, 61, 56-65. | 1.8 | 56 |
| 241 | A Clinical Prediction Model to Estimate Risk for 30-Day Adverse Events in Emergency Department Patients With Symptomatic Atrial Fibrillation. Annals of Emergency Medicine, 2011, 57, 1-12. | 0.3 | 56 |
| 242 | Relation of Morbid Obesity and Female Gender to Risk of Procedural Complications in Patients Undergoing Atrial Fibrillation Ablation. American Journal of Cardiology, 2013, 111, 368-373. | 0.7 | 56 |
| 243 | Clinical Pharmacogenetics Implementation Consortium (<scp>CPIC</scp>) Guideline for the Use of Potent Volatile Anesthetic Agents and Succinylcholine in the Context of <scp>RYR</scp>1 or <scp>CACNA</scp>1S Genotypes. Clinical Pharmacology and Therapeutics, 2019, 105, 1338-1344. | 2.3 | 56 |
| 244 | Genome-wide association analyses identify new Brugada syndrome risk loci and highlight a new mechanism of sodium channel regulation in disease susceptibility. Nature Genetics, 2022, 54, 232-239. | 9.4 | 55 |
| 245 | Plasma concentrations of quinidine, its major metabolites, and dihydroquinidine in patients with torsades de pointes. Clinical Pharmacology and Therapeutics, 1988, 43, 636-642. | 2.3 | 54 |
| 246 | New Mechanism Contributing to Drug-Induced Arrhythmia. Circulation, 2005, 112, 3239-3246. | 1.6 | 54 |
| 247 | Opportunities, resources, and techniques for implementing genomics in clinical care. Lancet, The, 2019, 394, 511-520. | 6.3 | 53 |
| 248 | Modulators of normal electrocardiographic intervals identified in a large electronic medical record. Heart Rhythm, 2011, 8, 271-277. | 0.3 | 52 |
| 249 | Risperidone Prolongs Cardiac Repolarization by Blocking the Rapid Component of the Delayed Rectifier Potassium Current. Journal of Cardiovascular Pharmacology, 2003, 41, 934-937. | 0.8 | 51 |
| 250 | Analysis for Genetic Modifiers of Disease Severity in Patients With Long-QT Syndrome Type 2. Circulation: Cardiovascular Genetics, 2015, 8, 447-456. | 5.1 | 51 |
| 251 | Genotype and risk of major bleeding during warfarin treatment. Pharmacogenomics, 2014, 15, 1973-1983. | 0.6 | 50 |
| 252 | CTNNA3 and SEMA3D: Promising loci for asthma exacerbation identified through multiple genome-wide association studies. Journal of Allergy and Clinical Immunology, 2015, 136, 1503-1510. | 1.5 | 50 |

| # | Article | IF | Citations |
|---|---|---|---|
| 253 | I Kr drug response is modulated by KCR1 in transfected cardiac and noncardiac cell lines. FASEB Journal, 2003, 17, 2263-2265. | 0.2 | 49 |
| 254 | A genome-wide association study of heparin-induced thrombocyto - penia using an electronic medical record. Thrombosis and Haemostasis, 2015, 113, 772-781. | 1.8 | 49 |
| 255 | Genetic and Clinical Risk Prediction Model for Postoperative Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2015, 8, 25-31. | 2.1 | 49 |
| 256 | Ibutilide and the Treatment of Atrial Arrhythmias. Circulation, 1996, 94, 1499-1502. | 1.6 | 49 |
| 257 | Electrophysiologic actions of high plasma concentrations of propranolol in human subjects. Journal of the American College of Cardiology, 1983, 2, 1134-1140. | 1.2 | 48 |
| 258 | Effects of Procainamide and Lidocaine on Defibrillation Energy Requirements in Patients Receiving Implantable Cardioverter Defibrillator Devices. Journal of Cardiovascular Electrophysiology, 1994, 5, 752-760. | 0.8 | 48 |
| 259 | In vivo identification of genes that modify ether-a-go-go-related gene activity in Caenorhabditis elegans may also affect human cardiac arrhythmia. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 11773-11778. | 3.3 | 48 |
| 260 | Evaluation of a Prediction Model for the Development of Atrial Fibrillation in a Repository of Electronic Medical Records. JAMA Cardiology, 2016, 1, 1007. | 3.0 | 48 |
| 261 | THE CARDIAC ION CHANNELS: Relevance to Management of Arrhythmias. Annual Review of Medicine, 1996, 47, 135-148. | 5.0 | 47 |
| 262 | Electronic Medical Records as a Tool in Clinical Pharmacology: Opportunities and Challenges. Clinical Pharmacology and Therapeutics, 2012, 91, 1083-1086. | 2.3 | 47 |
| 263 | Race-Specific Impact of Atrial Fibrillation Risk Factors in Blacks and Whites in the Southern Community Cohort Study. American Journal of Cardiology, 2012, 110, 1637-1642. | 0.7 | 47 |
| 264 | Penetrance of Hemochromatosis in HFE Genotypes Resulting in p.Cys282Tyr and p.[Cys282Tyr];[His63Asp] in the eMERGE Network. American Journal of Human Genetics, 2015, 97, 512-520. | 2.6 | 47 |
| 265 | Epinephrine-induced changes in serum potassium and cardiac repolarization and effects of pretreatment with propranolol and diltiazem. American Journal of Cardiology, 1996, 77, 1351-1355. | 0.7 | 46 |
| 266 | Leveraging the electronic health record to implement genomic medicine. Genetics in Medicine, 2013, 15, 270-271. | 1.1 | 46 |
| 267 | Apolipoprotein L1 VariantsÂand Blood Pressure Traits inÂAfrican Americans. Journal of the American College of Cardiology, 2017, 69, 1564-1574. | 1.2 | 46 |
| 268 | Persistent Atrial Fibrillation Is Associated With Reduced Risk of Torsades de Pointes in Patients With Drug-Induced Long QT Syndrome. Journal of the American College of Cardiology, 2008, 51, 836-842. | 1.2 | 43 |
| 269 | Biophysical Properties of 9 KCNQ1 Mutations Associated With Long-QT Syndrome. Circulation: Arrhythmia and Electrophysiology, 2009, 2, 417-426. | 2.1 | 43 |
| 270 | Recent Advances in Understanding the Molecular Mechanisms of the Long QT Syndrome. Journal of Cardiovascular Electrophysiology, 1995, 6, 1023-1031. | 0.8 | 42 |

| # | Article | IF | Citations |
|---|---|---|---|
| 271 | Abnormalities of the QT interval in primary disorders of autonomic failure. American Heart Journal, 1998, 136, 664-671. | 1.2 | 42 |
| 272 | Clinical, Genetic, and Biophysical Characterization of a Homozygous HERG Mutation Causing Severe Neonatal Long QT Syndrome. Pediatric Research, 2003, 53, 744-748. | 1.1 | 42 |
| 273 | Functional modeling in zebrafish demonstrates that the atrial-fibrillation-associated geneGREM2regulates cardiac laterality, cardiomyocyte differentiation and atrial rhythm. DMM Disease Models and Mechanisms, 2013, 6, 332-41. | 1.2 | 42 |
| 274 | Whole-exome sequencing in familial atrial fibrillation. European Heart Journal, 2014, 35, 2477-2483. | 1.0 | 42 |
| 275 | The Influence of Big (Clinical) Data and Genomics on Precision Medicine and Drug Development. Clinical Pharmacology and Therapeutics, 2018, 103, 409-418. | 2.3 | 42 |
| 276 | Probing the Virtual Proteome to Identify Novel Disease Biomarkers. Circulation, 2018, 138, 2469-2481. | 1.6 | 42 |
| 277 | Coding variants in RPL3L and MYZAP increase risk of atrial fibrillation. Communications Biology, 2018, 1, 68. | 2.0 | 42 |
| 278 | A current understanding of drug-induced QT prolongation and its implications for anticancer therapy. Cardiovascular Research, 2019, 115, 895-903. | 1.8 | 42 |
| 279 | High-throughput discovery of trafficking-deficient variants in the cardiac potassium channel KV11.1. Heart Rhythm, 2020, 17, 2180-2189. | 0.3 | 42 |
| 280 | Practical considerations in genomic decision support: The eMERGE experience. Journal of Pathology Informatics, 2015, 6, 50. | 0.8 | 42 |
| 281 | Predicting the Long-QT Genotype From Clinical Data. Circulation, 2000, 102, 2796-2798. | 1.6 | 41 |
| 282 | Polymorphism Screening in the Cardiac K+ Channel Gene KCNA5*. Clinical Pharmacology and Therapeutics, 2005, 77, 138-144. | 2.3 | 41 |
| 283 | SCN5A Mutation Type and a Genetic Risk Score Associate Variably With Brugada Syndrome Phenotype in SCN5A Families. Circulation Genomic and Precision Medicine, 2020, 13, e002911. | 1.6 | 41 |
| 284 | Phenome-Wide Association Studies. JAMA - Journal of the American Medical Association, 2022, 327, 75. | 3.8 | 41 |
| 285 | Dietary salt increases first-pass elimination of oral quinidine*. Clinical Pharmacology and Therapeutics, 1997, 61, 292-300. | 2.3 | 40 |
| 286 | Phosphorylation of the I Ks Channel Complex Inhibits Drug Block. Circulation, 2003, 108, 132-134. | 1.6 | 40 |
| 287 | Arrhythmogenic right ventricular cardiomyopathy due to a novel plakophilin 2 mutation: Wide spectrum of disease in mutation carriers within a family. Heart Rhythm, 2006, 3, 939-944. | 0.3 | 40 |
| 288 | Human Genomics and Its Impact on Arrhythmias. Trends in Cardiovascular Medicine, 2004, 14, 112-116. | 2.3 | 39 |

| # | Article | IF | Citations |
|---|---|---|---|
| 289 | Refining repolarization reserve. Heart Rhythm, 2011, 8, 1756-1757. | 0.3 | 39 |
| 290 | A multi-stage genome-wide association study of uterine fibroids in African Americans. Human Genetics, 2017, 136, 1363-1373. | 1.8 | 39 |
| 291 | An International Multicenter Evaluation of Type 5 Long QT Syndrome. Circulation, 2020, 141, 429-439. | 1.6 | 39 |
| 292 | Keep the QT interval: It is a reliable predictor of ventricular arrhythmias. Heart Rhythm, 2008, 5, 1213-1215. | 0.3 | 38 |
| 293 | Increased late sodium current contributes to long QT-related arrhythmia susceptibility in female mice. Cardiovascular Research, 2012, 95, 300-307. | 1.8 | 38 |
| 294 | Phenomeâ€wide association studies: a new method for functional genomics in humans. Journal of Physiology, 2017, 595, 4109-4115. | 1.3 | 38 |
| 295 | Defining Phenotypes from Clinical Data to Drive Genomic Research. Annual Review of Biomedical Data Science, 2018, 1, 69-92. | 2.8 | 38 |
| 296 | Building evidence and measuring clinical outcomes for genomic medicine. Lancet, The, 2019, 394, 604-610. | 6.3 | 38 |
| 297 | Anticancer drug-induced life-threatening ventricular arrhythmias: a World Health Organization pharmacovigilance study. European Heart Journal, 2021, 42, 3915-3928. | 1.0 | 38 |
| 298 | Characterization of Genome-Wide Association-Identified Variants for Atrial Fibrillation in African Americans. PLoS ONE, 2012, 7, e32338. | 1.1 | 37 |
| 299 | Generalization of Variants Identified by Genomeâ€Wide Association Studies for Electrocardiographic Traits in African Americans. Annals of Human Genetics, 2013, 77, 321-332. | 0.3 | 37 |
| 300 | Increased long QT and torsade de pointes reporting on tamoxifen compared with aromatase inhibitors. Heart, 2018, 104, 1859-1863. | 1.2 | 37 |
| 301 | Encainide. New England Journal of Medicine, 1988, 318, 1107-1115. | 13.9 | 36 |
| 302 | Polymorphisms in Beta-Adrenergic Receptor Genes in the Acquired Long QT Syndrome. Journal of Cardiovascular Electrophysiology, 2002, 13, 252-256. | 0.8 | 36 |
| 303 | Genomeâ€wide and Phenomeâ€wide Approaches to Understand Variable Drug Actions in Electronic Health Records. Clinical and Translational Science, 2018, 11, 112-122. | 1.5 | 36 |
| 304 | Association Between Early Postoperative Acetaminophen Exposure and Acute Kidney Injury in Pediatric Patients Undergoing Cardiac Surgery. JAMA Pediatrics, 2018, 172, 655. | 3.3 | 36 |
| 305 | SCN5A (Na <sub>V</sub> 1.5) Variant Functional Perturbation and Clinical Presentation. Circulation Genomic and Precision Medicine, 2018, 11, e002095. | 1.6 | 36 |
| 306 | Genome-wide study of resistant hypertension identified from electronic health records. PLoS ONE, 2017, 12, e0171745. | 1.1 | 36 |

| # | Article | IF | Citations |
|---|---|---|---|
| 307 | Mendelian randomization supports bidirectional causality between telomere length and clonal hematopoiesis of indeterminate potential. Science Advances, 2022, 8, eabl6579. | 4.7 | 36 |
| 308 | Congestive heart failure after acute myocardial infarction in patients receiving antiarrhythmic agents for ventricular premature complexes (Cardiac Arrhythmia Pilot Study). American Journal of Cardiology, 1989, 63, 393-398. | 0.7 | 35 |
| 309 | Drug-Induced J Point Elevation.. Journal of Cardiovascular Electrophysiology, 1999, 10, 219-223. | 0.8 | 35 |
| 310 | Suppression of Bidirectional Ventricular Tachycardia and Unmasking of Prolonged QT interval with Verapamil in Andersen's Syndrome. Journal of Cardiovascular Electrophysiology, 2004, 15, 119-119. | 0.8 | 35 |
| 311 | Identification of unique venous thromboembolism-susceptibility variants in African-Americans. Thrombosis and Haemostasis, 2017, 117, 758-768. | 1.8 | 35 |
| 312 | Improving the phenotype risk score as a scalable approach to identifying patients with Mendelian disease. Journal of the American Medical Informatics Association: JAMIA, 2019, 26, 1437-1447. | 2.2 | 35 |
| 313 | Accelerating Biomarker Discovery Through Electronic Health Records, Automated Biobanking, and Proteomics. Journal of the American College of Cardiology, 2019, 73, 2195-2205. | 1.2 | 35 |
| 314 | The Organic Cation Transporter, OCTN1, Expressed in the Human Heart, Potentiates Antagonism of the HERG Potassium Channel. Journal of Cardiovascular Pharmacology, 2009, 54, 63-71. | 0.8 | 34 |
| 315 | Systems biology and cardiac arrhythmias. Lancet, The, 2012, 380, 1498-1508. | 6.3 | 34 |
| 316 | Genetic Variants Associated with Serum Thyroid Stimulating Hormone (TSH) Levels in European Americans and African Americans from the eMERGE Network. PLoS ONE, 2014, 9, e111301. | 1.1 | 34 |
| 317 | Genome-wide Study Identifies Association between HLA-Bâˆ—55:01 and Self-Reported Penicillin Allergy. American Journal of Human Genetics, 2020, 107, 612-621. | 2.6 | 34 |
| 318 | Spectrum of antiarrhythmic response to encainide. American Journal of Cardiology, 1985, 56, 887-891. | 0.7 | 33 |
| 319 | Pharmacology and Toxicology of Nav1.5-ClassÂ1 Antiarrhythmic Drugs. Cardiac Electrophysiology Clinics, 2014, 6, 695-704. | 0.7 | 33 |
| 320 | Deep Mutational Scan of an SCN5A Voltage Sensor. Circulation Genomic and Precision Medicine, 2020, 13, e002786. | 1.6 | 33 |
| 321 | Prognostic significance of ventricular premature depolarizations measured 1 year after myocardial infraction in patient with early postinfarction asymptomatic ventricular arrhythmia. Journal of the American College of Cardiology, 1992, 20, 259-264. | 1.2 | 32 |
| 322 | Modulation of Cardiac Na <sup>+</sup> Current Phenotype by Î² <sub>1</sub> -Subunit Expression. Circulation Research, 1998, 83, 441-447. | 2.0 | 32 |
| 323 | Proarrhythmia as a pharmacogenomic entity: A critical review and formulation of a unifying hypothesis. Cardiovascular Research, 2005, 67, 419-425. | 1.8 | 32 |
| 324 | CMTR1 is associated with increased asthma exacerbations in patients taking inhaled corticosteroids. Immunity, Inflammation and Disease, 2015, 3, 350-359. | 1.3 | 32 |

| # | Article | IF | Citations |
|---|---|---|---|
| 325 | A Trans-Ethnic Genome-Wide Association Study of Uterine Fibroids. Frontiers in Genetics, 2019, 10, 511. | 1.1 | 32 |
| 326 | Genomewide Association Study of Platelet Reactivity and Cardiovascular Response in Patients Treated With Clopidogrel: A Study by the International Clopidogrel Pharmacogenomics Consortium. Clinical Pharmacology and Therapeutics, 2020, 108, 1067-1077. | 2.3 | 32 |
| 327 | QT prolongation and arrhythmia suppression. American Heart Journal, 1985, 109, 411-415. | 1.2 | 31 |
| 328 | A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Dofetilide in Patients with Inducible Sustained Ventricular Tachyarrhythmias. Journal of Cardiovascular Electrophysiology, 1995, 6, 687-699. | 0.8 | 31 |
| 329 | Modulation by Dietary Salt of Verapamil Disposition in Humans. Circulation, 1998, 98, 2702-2708. | 1.6 | 31 |
| 330 | Responding to the Clopidogrel Warning by the US Food and Drug Administration. Circulation, 2010, 122, 445-448. | 1.6 | 31 |
| 331 | Factors affecting the degree of QT prolongation with drug challenge in a large cohort of normal volunteers. Heart Rhythm, 2011, 8, 1530-1534. | 0.3 | 31 |
| 332 | Differential effects of O-demethyl encainide on induced and spontaneous arrhythmias in the conscious dog. American Journal of Cardiology, 1984, 54, 654-658. | 0.7 | 30 |
| 333 | Electrophysiologic effects of intravenous and oral sotalol for sustained ventricular tachycardia secondary to coronary artery disease. American Journal of Cardiology, 1988, 61, 1006-1011. | 0.7 | 30 |
| 334 | Left Atrial Hypertension After Repeated Catheter Ablations for Atrial Fibrillation. Journal of the American College of Cardiology, 2011, 57, 1918-1919. | 1.2 | 30 |
| 335 | Contrasting Nav1.8 Activity in Scn10a <sup> â^'/â^' </sup> Ventricular Myocytes and the Intact Heart. Journal of the American Heart Association, 2016, 5, . | 1.6 | 30 |
| 336 | Accelerating Precision Drug Development and Drug Repurposing by Leveraging Human Genetics. Assay and Drug Development Technologies, 2017, 15, 113-119. | 0.6 | 30 |
| 337 | Genetic Susceptibility for Atrial Fibrillation in Patients Undergoing Atrial Fibrillation Ablation. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e007676. | 2.1 | 30 |
| 338 | Quinidine-enhanced Î²-blockade during treatment with propafenone in extensive metabolizer human subjects. Clinical Pharmacology and Therapeutics, 1994, 55, 28-34. | 2.3 | 29 |
| 339 | Cardiac-enriched LIM domain protein fhl2 is required to generate IKs in a heterologous system. Cardiovascular Research, 2002, 56, 93-103. | 1.8 | 29 |
| 340 | Symptomatic burden as an endpoint to evaluate interventions in patients with atrial fibrillation. Heart Rhythm, 2005, 2, 544-549. | 0.3 | 29 |
| 341 | Pharmacogenomics: will the promise be fulfilled?. Nature Reviews Genetics, 2011, 12, 69-73. | 7.7 | 29 |
| 342 | A case study evaluating the portability of an executable computable phenotype algorithm across multiple institutions and electronic health record environments. Journal of the American Medical Informatics Association: JAMIA, 2018, 25, 1540-1546. | 2.2 | 29 |

| # | Article | IF | Citations |
|---|---|---|---|
| 343 | NovelKCNQ1 mutations associated with recessive and dominant congenital long QT Syndromes: Evidence for variable hearing phenotype associated with R518X. , 2000, 15, 387-388. | | 28 |
| 344 | Cardiovascular Pharmacogenomics. Circulation, 2003, 108, 3071-3074. | 1.6 | 28 |
| 345 | PheMap: a multi-resource knowledge base for high-throughput phenotyping within electronic health records. Journal of the American Medical Informatics Association: JAMIA, 2020, 27, 1675-1687. | 2.2 | 28 |
| 346 | Encainide disposition in patients with renal failure. Clinical Pharmacology and Therapeutics, 1986, 40, 64-70. | 2.3 | 27 |
| 347 | Flecainide enantiomers: Disposition in human subjects and electrophysiologic actions in vitro. Clinical Pharmacology and Therapeutics, 1989, 46, 584-590. | 2.3 | 27 |
| 348 | Pharmacology of the class 111 antiarrhythmic agent sematilide in patients with arrhythmias. American Journal of Cardiology, 1992, 69, 206-212. | 0.7 | 27 |
| 349 | Preprescription Genotyping. Circulation, 2001, 103, 1608-1610. | 1.6 | 27 |
| 350 | Cardiovascular Effects of Noncardiovascular Drugs. Circulation, 2009, 120, 1123-1132. | 1.6 | 27 |
| 351 | Heart failure and atrial tachyarrhythmia on abiraterone: A pharmacovigilance study. Archives of Cardiovascular Diseases, 2020, 113, 9-21. | 0.7 | 27 |
| 352 | Deep learning analysis of electrocardiogram for risk prediction of drug-induced arrhythmias and diagnosis of long QT syndrome. European Heart Journal, 2021, 42, 3948-3961. | 1.0 | 27 |
| 353 | Calmodulin kinase II activity is required for normal atrioventricular nodal conduction. Heart Rhythm, 2005, 2, 634-640. | 0.3 | 26 |
| 354 | Clinical and Genetic Factors Associated With Cutaneous Squamous Cell Carcinoma in Kidney and Heart Transplant Recipients. Transplantation Direct, 2015, 1, 1-7. | 0.8 | 26 |
| 355 | Inhibition of the Î±-Subunit of Phosphoinositide 3-Kinase in Heart Increases Late Sodium Current and Is Arrhythmogenic. Journal of Pharmacology and Experimental Therapeutics, 2018, 365, 460-466. | 1.3 | 26 |
| 356 | A phenome-wide association study to discover pleiotropic effects of PCSK9, APOB, and LDLR. Npj Genomic Medicine, 2019, 4, 3. | 1.7 | 26 |
| 357 | Development of a System for Postmarketing Population Pharmacokinetic and Pharmacodynamic Studies Using Realâ€World Data From Electronic Health Records. Clinical Pharmacology and Therapeutics, 2020, 107, 934-943. | 2.3 | 26 |
| 358 | Encainide disposition in patients with chronic cirrhosis. Clinical Pharmacology and Therapeutics, 1986, 40, 148-154. | 2.3 | 25 |
| 359 | Cardiovascular pharmacogenomics: current status and future directions. Journal of Human Genetics, 2016, 61, 79-85. | 1.1 | 25 |
| 360 | Human cardiac potassium channel DNA polymorphism modulates access to drug-binding site and causes drug resistance. Journal of Clinical Investigation, 2005, 115, 2209-2213. | 3.9 | 25 |

| # | Article | IF | Citations |
|---|---|---|---|
| 361 | Association of Pathogenic Variants in Hereditary Cancer Genes With Multiple Diseases. JAMA Oncology, 2022, 8, 835. | 3.4 | 25 |
| 362 | Comparison of the effects of placebo and encainide on programmed electrical stimulation and ventricular arrhythmia frequency. American Journal of Cardiology, 1982, 50, 305-312. | 0.7 | 24 |
| 363 | Pharmacogenetics of antiarrhythmic therapy. Expert Opinion on Pharmacotherapy, 2006, 7, 1583-1590. | 0.9 | 24 |
| 364 | A Rate-Independent Method of Assessing QT-RR Slope Following Conversion of Atrial Fibrillation. Journal of Cardiovascular Electrophysiology, 2007, 18, 636-641. | 0.8 | 24 |
| 365 | ACE I/D polymorphism associated with abnormal atrial and atrioventricular conduction in lone atrial fibrillation and structural heart disease: Implications for electrical remodeling. Heart Rhythm, 2009, 6, 1327-1332. | 0.3 | 24 |
| 366 | Assessment of a pharmacogenomic marker panel in a polypharmacy population identified from electronic medical records. Pharmacogenomics, 2013, 14, 735-744. | 0.6 | 24 |
| 367 | Common SCN10A variants modulate PR interval and heart rate response during atrial fibrillation. Europace, 2014, 16, 485-490. | 0.7 | 24 |
| 368 | The AFFORD Clinical Decision Aid to Identify Emergency Department Patients With Atrial Fibrillation at Low Risk for 30-Day Adverse Events. American Journal of Cardiology, 2015, 115, 763-770. | 0.7 | 24 |
| 369 | CYP2C19 and CES1 polymorphisms and efficacy of clopidogrel and aspirin dual antiplatelet therapy in patients with symptomatic intracranial atherosclerotic disease. Journal of Neurosurgery, 2016, 124, 1746-1751. | 0.9 | 24 |
| 370 | Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end pointsâ€"Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC). American Heart Journal, 2018, 198, 152-159. | 1.2 | 24 |
| 371 | Understanding the use of observational and randomized data in cardiovascular medicine. European Heart Journal, 2020, 41, 2571-2578. | 1.0 | 24 |
| 372 | The International Serious Adverse Events Consortium (iSAEC) phenotype standardization project for drug-induced torsades de pointes. European Heart Journal, 2013, 34, 1958-1963. | 1.0 | 23 |
| 373 | Integrating electronic health record genotype and phenotype datasets to transform patient care. Clinical Pharmacology and Therapeutics, 2016, 99, 298-305. | 2.3 | 23 |
| 374 | Opportunities and Challenges in Cardiovascular Pharmacogenomics. Circulation Research, 2018, 122, 1176-1190. | 2.0 | 23 |
| 375 | Association of Thyroid Function Genetic Predictors With Atrial Fibrillation. JAMA Cardiology, 2019, 4, 136. | 3.0 | 23 |
| 376 | Genomeâ€Wide Association and Functional Studies Reveal Novel Pharmacological Mechanisms for Allopurinol. Clinical Pharmacology and Therapeutics, 2019, 106, 623-631. | 2.3 | 23 |
| 377 | SCN5A Variation Is Associated With Electrocardiographic Traits in the Jackson Heart Study. Circulation: Cardiovascular Genetics, 2011, 4, 139-144. | 5.1 | 22 |
| 378 | Variants in the SCN5A Promoter Associated With Various Arrhythmia Phenotypes. Journal of the American Heart Association, 2016, 5, . | 1.6 | 22 |

| # | Article | IF | Citations |
|---|---|---|---|
| 379 | The Future of Cardiovascular Therapeutics. Circulation, 2016, 133, 2610-2617. | 1.6 | 22 |
| 380 | Using Human â€˜Experiments of Natureâ€™ to Predict Drug Safety Issues: An Example with PCSK9 Inhibitors. Drug Safety, 2018, 41, 303-311. | 1.4 | 22 |
| 381 | Relationship between very low low-density lipoprotein cholesterol concentrations not due to statin therapy and risk of type 2 diabetes: A US-based cross-sectional observational study using electronic health records. PLoS Medicine, 2018, 15, e1002642. | 3.9 | 22 |
| 382 | Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9. BMC Cardiovascular Disorders, 2019, 19, 240. | 0.7 | 22 |
| 383 | Antiarrhythmic Drugs:. Past, Present, and Future. Journal of Cardiovascular Electrophysiology, 2003, 14, 1389-1396. | 0.8 | 21 |
| 384 | Future of antiarrhythmic drugs. Current Opinion in Cardiology, 2006, 21, 361-367. | 0.8 | 21 |
| 385 | Pharmacogenomics at the Tipping Point: Challenges and Opportunities. Clinical Pharmacology and Therapeutics, 2011, 89, 323-327. | 2.3 | 21 |
| 386 | Applied Pharmacogenomics in Cardiovascular Medicine. Annual Review of Medicine, 2014, 65, 81-94. | 5.0 | 21 |
| 387 | KCNE1 induces fenestration in the Kv7.1/KCNE1 channel complex that allows for highly specific pharmacological targeting. Nature Communications, 2016, 7, 12795. | 5.8 | 21 |
| 388 | CYP2D6 genotype and adverse events to risperidone in children and adolescents. Pediatric Research, 2019, 85, 602-606. | 1.1 | 21 |
| 389 | GRIK5 Genetically Regulated Expression Associated with Eye and Vascular Phenomes: Discovery through Iteration among Biobanks, Electronic Health Records, and Zebrafish. American Journal of Human Genetics, 2019, 104, 503-519. | 2.6 | 21 |
| 390 | Mexiletine and tocainide: A comparison of antiarrhythmic efficacy, adverse effects, and predictive value of lidocaine testing. Clinical Pharmacology and Therapeutics, 1989, 45, 553-561. | 2.3 | 20 |
| 391 | The US Food and Drug Administration Cardiorenal Advisory Panel and the Drug Approval Process. Circulation, 2005, 111, 1697-1702. | 1.6 | 20 |
| 392 | Enabling Genomic-Phenomic Association Discovery without Sacrificing Anonymity. PLoS ONE, 2013, 8, e53875. | 1.1 | 20 |
| 393 | A Common Variant on Chromosome 4q25 is Associated With Prolonged PR Interval in Subjects With and Without Atrial Fibrillation. American Journal of Cardiology, 2014, 113, 309-313. | 0.7 | 20 |
| 394 | Merging Electronic Health Record Data and Genomics for Cardiovascular Research. Circulation: Cardiovascular Genetics, 2016, 9, 193-202. | 5.1 | 20 |
| 395 | Considerations for drug interactions on QTc interval in exploratory COVID-19 treatment. Heart Rhythm, 2020, 17, e231-e232. | 0.3 | 20 |
| 396 | A retrospective approach to evaluating potential adverse outcomes associated with delay of procedures for cardiovascular and cancer-related diagnoses in the context of COVID-19. Journal of Biomedical Informatics, 2021, 113, 103657. | 2.5 | 20 |

| # | Article | IF | Citations |
|---|---|---|---|
| 397 | Shared Decision Making in Cardiac Electrophysiology Procedures and Arrhythmia Management. Circulation: Arrhythmia and Electrophysiology, 2021, 14, CIRCEP121007958. | 2.1 | 20 |
| 398 | Effect of Fluosol-DA on infarct morphology and vulnerability to ventricular arrhythmia. American Heart Journal, 1986, 112, 1192-1201. | 1.2 | 19 |
| 399 | Brugada-Type ECG Pattern and Extreme QRS Complex Widening with Propafenone Overdose. Journal of Cardiovascular Electrophysiology, 2006, 17, 565-566. | 0.8 | 19 |
| 400 | Recombinase-mediated cassette exchange to rapidly and efficiently generate mice with human cardiac sodium channels. Genesis, 2006, 44, 556-564. | 0.8 | 19 |
| 401 | QT variability during initial exposure to sotalol: experience based on a large electronic medical record. Europace, 2013, 15, 1791-1797. | 0.7 | 19 |
| 402 | Protein structure aids predicting functional perturbation of missense variants in SCN5A and KCNQ1. Computational and Structural Biotechnology Journal, 2019, 17, 206-214. | 1.9 | 19 |
| 403 | Genome-Wide Association Study of Serum Creatinine Levels during Vancomycin Therapy. PLoS ONE, 2015, 10, e0127791. | 1.1 | 19 |
| 404 | Integrating gene expression and clinical data to identify drug repurposing candidates for hyperlipidemia and hypertension. Nature Communications, 2022, 13, 46. | 5.8 | 19 |
| 405 | Arrhythmias as Presentation of Genetic Cardiomyopathy. Circulation Research, 2022, 130, 1698-1722. | 2.0 | 19 |
| 406 | An Underrecognized Challenge in Evaluating Postmarketing Drug Safety. Circulation, 2005, 111, 246-248. | 1.6 | 18 |
| 407 | Informatic and Functional Approaches to Identifying a Regulatory Region for the Cardiac Sodium Channel. Circulation Research, 2011, 109, 38-46. | 2.0 | 18 |
| 408 | Calcium channel blockers as drug repurposing candidates for gestational diabetes: Mining large scale genomic and electronic health records data to repurpose medications. Pharmacological Research, 2018, 130, 44-51. | 3.1 | 18 |
| 409 | Identification of Central Regulators of Calcium Signaling and ECMâ€“Receptor Interaction Genetically Associated With the Progression and Recurrence of Atrial Fibrillation. Frontiers in Genetics, 2018, 9, 162. | 1.1 | 18 |
| 410 | Predictive Accuracy of a Polygenic Risk Score for Postoperative Atrial Fibrillation After Cardiac Surgery. Circulation Genomic and Precision Medicine, 2021, 14, e003269. | 1.6 | 18 |
| 411 | Association Between a Common, Benign Genotype and Unnecessary Bone Marrow Biopsies Among African American Patients. JAMA Internal Medicine, 2021, 181, 1100. | 2.6 | 18 |
| 412 | Arrhythmia Variant Associations and Reclassifications in the eMERGE-III Sequencing Study. Circulation, 2022, 145, 877-891. | 1.6 | 18 |
| 413 | Molecular basis for the antigenicity of lidocaine analogs: Tocainide and mexiletine. American Heart Journal, 1984, 107, 585-589. | 1.2 | 17 |
| 414 | Pharmacokinetic and Pharmacodynamic Interaction of N-Acetyl Procainamide and Procainamide in Humans. Journal of Cardiovascular Pharmacology, 1989, 14, 364-373. | 0.8 | 17 |

| # | Article | IF | Citations |
|---|---|---|---|
| 415 | A Surprising New Arrhythmia Mechanism in Heart Failure. Circulation Research, 2003, 93, 589-591. | 2.0 | 17 |
| 416 | Rateâ€Independent QT Shortening During Exercise in Healthy Subjects: Terminal Repolarization Does Not Shorten with Exercise. Journal of Cardiovascular Electrophysiology, 2008, 19, 1284-1288. | 0.8 | 17 |
| 417 | Cardiovascular Pharmacogenomics: Current Status and Future Directionsâ€"Report of a National Heart, Lung, and Blood Institute Working Group. Journal of the American Heart Association, 2012, 1, e000554. | 1.6 | 17 |
| 418 | Using systems approaches to address challenges for clinical implementation of pharmacogenomics. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2014, 6, 125-135. | 6.6 | 17 |
| 419 | Candidate gene approach to identifying rare genetic variants associated with lone atrial fibrillation. Heart Rhythm, 2014, 11, 46-52. | 0.3 | 17 |
| 420 | Deciphering Signaling Pathway Networks to Understand the Molecular Mechanisms of Metformin Action. PLoS Computational Biology, 2015, 11, e1004202. | 1.5 | 17 |
| 421 | A conceptual model for translating omic data into clinical action. Journal of Pathology Informatics, 2015, 6, 46. | 0.8 | 17 |
| 422 | Tocainide plus quinidine for treatment of ventricular arrhythmias. American Journal of Cardiology, 1988, 61, 570-573. | 0.7 | 16 |
| 423 | A prognostic model based on readily available clinical data enriched aÂpre-emptive pharmacogenetic testing program. Journal of Clinical Epidemiology, 2016, 72, 107-115. | 2.4 | 16 |
| 424 | Electrophysiologic and hemodynamic effects of chronic oral therapy with the Î±2-agonists clonidine and tiamenidine in hypertensive volunteers. Clinical Pharmacology and Therapeutics, 1988, 43, 648-654. | 2.3 | 15 |
| 425 | Clinical features of arrhythmia aggravation by antiarrhythmic drugs and their implications for basic mechanisms. Drug Development Research, 1990, 19, 153-172. | 1.4 | 15 |
| 426 | Mechanisms underlying variability in response to drug therapy: implications for amiodarone use. American Journal of Cardiology, 1999, 84, 29-36. | 0.7 | 15 |
| 427 | Sympathetic Activation Enhances QT Prolongation by Quinidine. Journal of Cardiovascular Electrophysiology, 2001, 12, 9-14. | 0.8 | 15 |
| 428 | Coinheritance of long QT syndrome and Kearns-Sayre syndrome. Heart Rhythm, 2007, 4, 1568-1572. | 0.3 | 15 |
| 429 | Autonomic Tone Attenuates Drug-Induced QT Prolongation. Journal of Cardiovascular Electrophysiology, 2007, 18, 960-964. | 0.8 | 15 |
| 430 | A Genotype-Dependent Intermediate ECG Phenotype in Patients With Persistent Lone Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2009, 2, 24-28. | 2.1 | 15 |
| 431 | Admixture Mapping and Subsequent Fine-Mapping Suggests a Biologically Relevant and Novel Association on Chromosome 11 for Type 2 Diabetes in African Americans. PLoS ONE, 2014, 9, e86931. | 1.1 | 15 |
| 432 | A Genome-Wide Association Study to Identify Genomic Modulators of Rate Control Therapy in Patients With Atrial Fibrillation. American Journal of Cardiology, 2014, 114, 593-600. | 0.7 | 15 |

| # | Article | IF | Citations |
|---|---|---|---|
| 433 | Phenotype-Driven Plasma Biobanking Strategies and Methods. Journal of Personalized Medicine, 2015, 5, 140-152. | 1.1 | 15 |
| 434 | Genetic Interactions with Age, Sex, Body Mass Index, and Hypertension in Relation to Atrial Fibrillation: The AFGen Consortium. Scientific Reports, 2017, 7, 11303. | 1.6 | 15 |
| 435 | Evaluating statistical approaches to leverage large clinical datasets for uncovering therapeutic and adverse medication effects. Bioinformatics, 2018, 34, 2988-2996. | 1.8 | 15 |
| 436 | Clopidogrel Pharmacogenetics â€" Why the Wait?. New England Journal of Medicine, 2019, 381, 1677-1678. | 13.9 | 15 |
| 437 | SCN5A variant R222Q generated abnormal changes in cardiac sodium current and action potentials in murine myocytes and Purkinje cells. Heart Rhythm, 2019, 16, 1676-1685. | 0.3 | 15 |
| 438 | Response to the editorial â€œCOVID-19 in patients with cardiovascular diseasesâ€• Archives of Cardiovascular Diseases, 2020, 113, 367-368. | 0.7 | 15 |
| 439 | Mechanistic Phenotypes: An Aggregative Phenotyping Strategy to Identify Disease Mechanisms Using GWAS Data. PLoS ONE, 2013, 8, e81503. | 1.1 | 15 |
| 440 | The 3D mutational constraint on amino acid sites in the human proteome. Nature Communications, 2022, 13, . | 5.8 | 15 |
| 441 | Genetic determinants of response to cardiovascular drugs. Current Opinion in Cardiology, 2012, 27, 253-261. | 0.8 | 14 |
| 442 | Stem Cellâ€"Derived Cardiomyocytes as a Tool for Studying Proarrhythmia. Circulation, 2013, 127, 1641-1643. | 1.6 | 14 |
| 443 | An Allosteric Mechanism for Drug Block of the Human Cardiac Potassium Channel KCNQ1. Molecular Pharmacology, 2013, 83, 481-489. | 1.0 | 14 |
| 444 | Pharmacogenetics of Potassium Channel Blockers. Cardiac Electrophysiology Clinics, 2016, 8, 385-393. | 0.7 | 14 |
| 445 | Influence of Human Leukocyte Antigen (<scp>HLA</scp>) Alleles and Killer Cell Immunoglobulinâ€Like Receptors (<scp>KIR</scp>) Types on Heparinâ€Induced Thrombocytopenia (<scp>HIT</scp>). Pharmacotherapy, 2017, 37, 1164-1171. | 1.2 | 14 |
| 446 | Hypertension genetic risk score is associated with burden of coronary heart disease among patients referred for coronary angiography. PLoS ONE, 2018, 13, e0208645. | 1.1 | 14 |
| 447 | How Will Genetics Inform the Clinical Care of Atrial Fibrillation?. Circulation Research, 2020, 127, 111-127. | 2.0 | 14 |
| 448 | Mortality Among Patients With Early-Onset Atrial Fibrillation and Rare Variants in Cardiomyopathy and Arrhythmia Genes. JAMA Cardiology, 2022, 7, 733. | 3.0 | 14 |
| 449 | Pharmacologic reversal of hypotensive effect complicating antiarrhythmic therapy with bretylium. Clinical Pharmacology and Therapeutics, 1982, 32, 313-321. | 2.3 | 13 |
| 450 | Electrophysiology of O-Demethyl Encainide in a Canine Model of Sustained Ventricular Tachycardia. Journal of Cardiovascular Pharmacology, 1984, 6, 588-595. | 0.8 | 13 |

| # | Article | IF | Citations |
|---|---|---|---|
| 451 | Lack of Triggered Automaticity Despite Repolarization Abnormalities due to Bepridil and Lidoflazine. PACE - Pacing and Clinical Electrophysiology, 1990, 13, 30-36. | 0.5 | 13 |
| 452 | On the relationship among QT interval, atrial fibrillation, and torsade de pointes. Europace, 2007, 9, iv1-iv3. | 0.7 | 13 |
| 453 | Personalized medicine and the genotypeâ€“phenotype dilemma. Journal of Interventional Cardiac Electrophysiology, 2011, 31, 17-23. | 0.6 | 13 |
| 454 | Cardiovascular Pharmacogenomics: The Future of Cardiovascular Therapeutics?. Canadian Journal of Cardiology, 2013, 29, 58-66. | 0.8 | 13 |
| 455 | A study paradigm integrating prospective epidemiologic cohorts and electronic health records to identify disease biomarkers. Nature Communications, 2018, 9, 3522. | 5.8 | 13 |
| 456 | The polygenic architecture of left ventricular mass mirrors the clinical epidemiology. Scientific Reports, 2020, 10, 7561. | 1.6 | 13 |
| 457 | KCNH2 pharmacogenomics summary. Pharmacogenetics and Genomics, 2010, 20, 775-777. | 0.7 | 13 |
| 458 | Molecular characterization and investigation of the role of genetic variation in phenotypic variability and response to treatment in a large pediatric Marfan syndrome cohort. Genetics in Medicine, 2022, 24, 1045-1053. | 1.1 | 13 |
| 459 | Clinical Pharmacokinetics of Encainide. Clinical Pharmacokinetics, 1988, 14, 141-147. | 1.6 | 12 |
| 460 | Novel Brugada SCN5A mutation causing sudden death in children. Heart Rhythm, 2005, 2, 540-543. | 0.3 | 12 |
| 461 | Pharmacogenomics and Cardiovascular Disease. Current Cardiology Reports, 2013, 15, 376. | 1.3 | 12 |
| 462 | Dantrolene. Circulation, 2014, 129, 834-836. | 1.6 | 12 |
| 463 | Genetic variation in the Î²1-adrenergic receptor is associated with the risk of atrial fibrillation after cardiac surgery. American Heart Journal, 2014, 167, 101-108.e1. | 1.2 | 12 |
| 464 | Identifying genetically driven clinical phenotypes using linear mixed models. Nature Communications, 2016, 7, 11433. | 5.8 | 12 |
| 465 | Torsades de pointes with high-dose loperamide. Journal of Electrocardiology, 2017, 50, 355-357. | 0.4 | 12 |
| 466 | A Patient With Elevated Plasma High Density Lipoprotein (HDL) and Facial Flushing. Journal of Clinical Lipidology, 2017, 11, 794. | 0.6 | 12 |
| 467 | On the Potential of Preemptive Genotyping Towards Preventing Medication-Related Adverse Events: Results from the South Korean National Health Insurance Database. Drug Safety, 2017, 40, 1-2. | 1.4 | 12 |
| 468 | Atropine-induced sinus tachycardia protects against exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia. Europace, 2020, 22, 643-648. | 0.7 | 12 |

| # | Article | IF | Citations |
|---|---|---|---|
| 469 | Polygenic Risk Score to Identify Subclinical Coronary Heart Disease Risk in Young Adults. Circulation Genomic and Precision Medicine, 2021, 14, e003341. | 1.6 | 12 |
| 470 | Common Ancestry-Specific Ion Channel Variants Predispose to Drug-Induced Arrhythmias. Circulation, 2022, 145, 299-308. | 1.6 | 12 |
| 471 | Risk factor interactions and genetic effects associated with post-operative atrial fibrillation. Pacific Symposium on Biocomputing Pacific Symposium on Biocomputing, 2006, , 584-95. | 0.7 | 12 |
| 472 | The reckoning: The return of genomic results to 1444 participants across the eMERGE3 Network. Genetics in Medicine, 2022, 24, 1130-1138. | 1.1 | 12 |
| 473 | Potential Applications of Free Drug Level Monitoring in Cardiovascular Therapyâ€. Clinical Pharmacokinetics, 1984, 9, 79-83. | 1.6 | 11 |
| 474 | Effects of Drug Metabolism, Metabolites, and Stereoselectivity on Antiarrhythmic Drug Action. Journal of Cardiovascular Electrophysiology, 1990, 1, 238-260. | 0.8 | 11 |
| 475 | Genetically determined stereoselective excretion of encainide in humans and electrophysiologic effects of its enantiomers in canine cardiac Purkinje fibers. Clinical Pharmacology and Therapeutics, 1991, 49, 488-496. | 2.3 | 11 |
| 476 | Bidirectional ventricular tachycardia and channelopathy. American Journal of Cardiology, 2003, 92, 991-995. | 0.7 | 11 |
| 477 | Acute kidney injury risk-based screening in pediatric inpatients: a pragmatic randomized trial. Pediatric Research, 2020, 87, 118-124. | 1.1 | 11 |
| 478 | A Bayesian method to estimate variant-induced disease penetrance. PLoS Genetics, 2020, 16, e1008862. | 1.5 | 11 |
| 479 | Phenotyping coronavirus disease 2019 during a global health pandemic: Lessons learned from the characterization of an early cohort. Journal of Biomedical Informatics, 2021, 117, 103777. | 2.5 | 11 |
| 480 | Cardiovascular and Renal Advisory Panel of the US Food and Drug Administration Considers Four Drugs. Circulation, 1997, 95, 2335-2335. | 1.6 | 11 |
| 481 | Electropharmacologic Synergism With Mexiletine and Quinidine. Journal of Cardiovascular Pharmacology, 1987, 9, 840-846. | 0.8 | 11 |
| 482 | Control of ventricular preexcitation and associated arrhythmias by encainide. American Heart Journal, 1981, 102, 794-797. | 1.2 | 10 |
| 483 | Stereoselective Determination of Flecainide in Human Plasma by High-Performance Liquid Chromatography with Fluorescence Detection. Journal of Pharmaceutical Sciences, 1990, 79, 91-95. | 1.6 | 10 |
| 484 | FDA Panel Report: January 1998. Circulation, 1998, 97, 2295-2296. | 1.6 | 10 |
| 485 | Genetic polymorphisms, drugs, and proarrhythmia. Journal of Interventional Cardiac Electrophysiology, 2003, 9, 131-135. | 0.6 | 10 |
| 486 | The molecular genetics of arrhythmias. Cardiovascular Research, 2005, 67, 343-346. | 1.8 | 10 |

| # | Article | IF | Citations |
|---|---|---|---|
| 487 | Examining Rare and Low-Frequency Genetic Variants Previously Associated With Lone or Familial Forms of Atrial Fibrillation in an Electronic Medical Record System. Circulation: Cardiovascular Genetics, 2015, 8, 58-63. | 5.1 | 10 |
| 488 | Rare variants in genes encoding the cardiac sodium channel and associated compounds and their impact on outcome of catheter ablation of atrial fibrillation. PLoS ONE, 2017, 12, e0183690. | 1.1 | 10 |
| 489 | A Decision-Theoretic Approach to Panel-Based, Preemptive Genotyping. MDM Policy and Practice, 2019, 4, 238146831986433. | 0.5 | 10 |
| 490 | Adverse Events Associated with Risperidone Use in Pediatric Patients: A Retrospective Biobank Study. Drugs - Real World Outcomes, 2019, 6, 59-71. | 0.7 | 10 |
| 491 | Genomic Medicine Year in Review: 2019. American Journal of Human Genetics, 2019, 105, 1072-1075. | 2.6 | 10 |
| 492 | Pleiotropy in the Genetic Predisposition to Rheumatoid Arthritis: A Phenomeâ€Wide Association Study and Inverse Varianceâ€“Weighted Metaâ€Analysis. Arthritis and Rheumatology, 2020, 72, 1483-1492. | 2.9 | 10 |
| 493 | DDIWAS: High-throughput electronic health record-based screening of drug-drug interactions. Journal of the American Medical Informatics Association: JAMIA, 2021, 28, 1421-1430. | 2.2 | 10 |
| 494 | Estimating the Posttest Probability of Long QT Syndrome Diagnosis for Rare KCNH2 Variants. Circulation Genomic and Precision Medicine, 2021, 14, e003289. | 1.6 | 10 |
| 495 | Bretylium: Relations between plasma concentrations and pharmacologic actions in high-frequency ventricular arrhythmias. American Journal of Cardiology, 1985, 55, 395-401. | 0.7 | 9 |
| 496 | RISK FACTOR INTERACTIONS AND GENETIC EFFECTS ASSOCIATED WITH POST-OPERATIVE ATRIAL FIBRILLATION. , 2005, , . | | 9 |
| 497 | Genetic nondiscrimination legislation: a critical prerequisite for pharmacogenomics data sharing. Pharmacogenomics, 2007, 8, 519-519. | 0.6 | 9 |
| 498 | Genetic variation in the rhythmonome: ethnic variation and haplotype structure in candidate genes for arrhythmias. Pharmacogenomics, 2009, 10, 1043-1053. | 0.6 | 9 |
| 499 | Atrial fibrillation and flutter outcomes and risk determination (AFFORD): Design and rationale. Journal of Cardiology, 2011, 58, 124-130. | 0.8 | 9 |
| 500 | Multiplex ligation-dependent probe amplification copy number variant analysis in patients with acquired long QT syndrome. Europace, 2015, 17, 635-641. | 0.7 | 9 |
| 501 | Leveraging Human Genetics to Identify Safety Signals Prior to Drug Marketing Approval and Clinical Use. Drug Safety, 2020, 43, 567-582. | 1.4 | 9 |
| 502 | Quinidine in the Management of Recurrent Ventricular Arrhythmias. JACC: Clinical Electrophysiology, 2021, 7, 1254-1263. | 1.3 | 9 |
| 503 | Comparing medical history data derived from electronic health records and survey answers in the All of Us Research Program. Journal of the American Medical Informatics Association: JAMIA, 2022, 29, 1131-1141. | 2.2 | 9 |
| 504 | Dominant negative effects of SCN5A missense variants. Genetics in Medicine, 2022, 24, 1238-1248. | 1.1 | 9 |

| # | Article | IF | Citations |
|---|---|---|---|
| 505 | ABO O blood group as a risk factor for platelet reactivity in heparin-induced thrombocytopenia. Blood, 2022, 140, 274-284. | 0.6 | 9 |
| 506 | Indications for Different Modes of Surgical Therapy in Medically Refractory Ventricular Arrhythmias. Annals of Surgery, 1986, 203, 679-684. | 2.1 | 8 |
| 507 | Toward a molecular view of cardiac arrhythmogenesis. Trends in Cardiovascular Medicine, 1994, 4, 278-285. | 2.3 | 8 |
| 508 | Himalayan T Waves in the Congenital Long-QT Syndrome. Circulation, 2005, 111, e161. | 1.6 | 8 |
| 509 | Probing the mechanisms underlying modulation of quinidine sensitivity to cardiac I<sub>Ks</sub> block by protein kinase Aâ€mediated I<sub>Ks</sub> phosphorylation. British Journal of Pharmacology, 2009, 157, 952-961. | 2.7 | 8 |
| 510 | Brugada syndrome: Lots of questions, some answers. Heart Rhythm, 2010, 7, 47-49. | 0.3 | 8 |
| 511 | Genomic contributors to atrial electroanatomical remodeling and atrial fibrillation progression: Pathway enrichment analysis of GWAS data. Scientific Reports, 2016, 6, 36630. | 1.6 | 8 |
| 512 | Investigating the Genetic Architecture of the PR Interval Using Clinical Phenotypes. Circulation: Cardiovascular Genetics, 2017, 10, . | 5.1 | 8 |
| 513 | Clinical Features Associated With Nascent Left Ventricular Diastolic Dysfunction in a Population Aged 40 to 55 Years. American Journal of Cardiology, 2018, 121, 1552-1557. | 0.7 | 8 |
| 514 | Multiple mechanisms underlie increased cardiac late sodium current. Heart Rhythm, 2019, 16, 1091-1097. | 0.3 | 8 |
| 515 | Real-time visualization of titin dynamics reveals extensive reversible photobleaching in human induced pluripotent stem cell-derived cardiomyocytes. American Journal of Physiology - Cell Physiology, 2020, 318, C163-C173. | 2.1 | 8 |
| 516 | Variants in ADRB1 and CYP2C9: Association with Response to Atenolol and Losartan in Marfan Syndrome. Journal of Pediatrics, 2020, 222, 213-220.e5. | 0.9 | 8 |
| 517 | Genetic Thyrotropin Regulation of Atrial Fibrillation Risk Is Mediated Through an Effect on Height. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 2124-2132. | 1.8 | 8 |
| 518 | Creation and Validation of an EMR-based Algorithm for Identifying Major Adverse Cardiac Events while on Statins. AMIA Summits on Translational Science Proceedings, 2014, 2014, 112-9. | 0.4 | 8 |
| 519 | Selection of an antiarrhythmic drug for a sudden-death-prevention trial. American Heart Journal, 1982, 103, 737-745. | 1.2 | 7 |
| 520 | The Antiarrhythmic Activity of Meobentine Sulfate in Man. Journal of Cardiovascular Pharmacology, 1984, 6, 650-656. | 0.8 | 7 |
| 521 | The development and testing of intravenous dosing regimens: Application to flecainide for the suppression of ventricular arrhythmias. Clinical Pharmacology and Therapeutics, 1988, 43, 499-508. | 2.3 | 7 |
| 522 | Pharmacokinetic Profile of Encainide. Clinical Pharmacology and Therapeutics, 1989, 45, 692-694. | 2.3 | 7 |

| # | Article | IF | Citations |
|---|---|---|---|
| 523 | Defective Ion Channel Function in the Long QT Syndrome: Multiple Unexpected Mechanisms. Journal of Molecular and Cellular Cardiology, 2001, 33, 185-187. | 0.9 | 7 |
| 524 | A New Role for Calmodulin in Ion Channel Biology. Circulation Research, 2006, 98, 979-981. | 2.0 | 7 |
| 525 | Arrhythmia Pharmacogenomics: Methodological Considerations. Current Pharmaceutical Design, 2009, 15, 3734-3741. | 0.9 | 7 |
| 526 | Populationâ€specific singleâ€nucleotide polymorphism confersÂincreased risk of venous thromboembolism in African Americans. Molecular Genetics & Genomic Medicine, 2016, 4, 513-520. | 0.6 | 7 |
| 527 | Defining a Contemporary Ischemic Heart Disease Genetic Risk Profile Using Historical Data. Circulation: Cardiovascular Genetics, 2016, 9, 521-530. | 5.1 | 7 |
| 528 | Evaluation of the F2R IVS-14A/T PAR1 polymorphism with subsequent cardiovascular events and bleeding in patients who have undergone percutaneous coronary intervention. Journal of Thrombosis and Thrombolysis, 2016, 41, 656-662. | 1.0 | 7 |
| 529 | Evaluation of a Novel System to Enhance Clinicians' Recognition of Preadmission Adverse Drug Reactions. Applied Clinical Informatics, 2018, 09, 313-325. | 0.8 | 7 |
| 530 | CNV Association of Diverse Clinical Phenotypes from eMERGE reveals novel disease biology underlying cardiovascular disease. International Journal of Cardiology, 2020, 298, 107-113. | 0.8 | 7 |
| 531 | KCNQ1 and Long QT Syndrome in 1/45 Amish. Circulation Genomic and Precision Medicine, 2020, 13, e003133. | 1.6 | 7 |
| 532 | Genomeâ€Wide Approach to Measure Variantâ€Based Heritability of Drug Outcome Phenotypes. Clinical Pharmacology and Therapeutics, 2021, 110, 714-722. | 2.3 | 7 |
| 533 | Non-pulmonary vein mediated atrial fibrillation: A novel sub-phenotype. PLoS ONE, 2017, 12, e0184354. | 1.1 | 7 |
| 534 | Rare Variation in Drug Metabolism and Long QT Genes and the Genetic Susceptibility to Acquired Long QT Syndrome. Circulation Genomic and Precision Medicine, 2022, 15, CIRCGEN121003391. | 1.6 | 7 |
| 535 | Genome-wide association study of platelet factor 4/heparin antibodies in heparin-induced thrombocytopenia. Blood Advances, 2022, 6, 4137-4146. | 2.5 | 7 |
| 536 | QT Bumps: Unraveling the Mechanisms. Journal of Cardiovascular Electrophysiology, 2001, 12, 1379-1380. | 0.8 | 6 |
| 537 | Genetic variation in the UGT1A locus is associated with simvastatin efficacy in a clinical practice setting. Pharmacogenomics, 2014, 15, 1739-1747. | 0.6 | 6 |
| 538 | Real-time clinical note monitoring to detect conditions for rapid follow-up: A case study of clinical trial enrollment in drug-induced torsades de pointes and Stevens-Johnson syndrome. Journal of the American Medical Informatics Association: JAMIA, 2021, 28, 126-131. | 2.2 | 6 |
| 539 | Robust, flexible, and scalable tests for Hardyâ€“Weinberg equilibrium across diverse ancestries. Genetics, 2021, 218, . | 1.2 | 6 |
| 540 | Recurrent Ventricular Tachycardia in the Absence of Overt Heart Disease. Southern Medical Journal, 1981, 74, 1090-1094. | 0.3 | 5 |

| # | Article | IF | Citations |
|---|---|---|---|
| 541 | Clinical Pharmacology of the New Antiarrhythmic Encainide. Clinical Progress in Pacing and Electrophysiology, 1984, 2, 112-119. | 0.3 | 5 |
| 542 | A Prolonged QTc Interval. Medical Toxicology and Adverse Drug Experience, 1989, 4, 400-411. | 0.8 | 5 |
| 543 | Recainam dose titration and pharmacokinetics in patients with resistant arrhythmias. Clinical Pharmacology and Therapeutics, 1989, 46, 324-334. | 2.3 | 5 |
| 544 | Immediate- versus controlled-release disopyramide: Importance of saturable binding. Clinical Pharmacology and Therapeutics, 1993, 54, 16-22. | 2.3 | 5 |
| 545 | Loss of quinidine gluconate injection in a polyvinyl chloride infusion system. American Journal of Health-System Pharmacy, 1996, 53, 655-658. | 0.5 | 5 |
| 546 | Cardiovascular News. Circulation, 1998, 97, 1107-1107. | 1.6 | 5 |
| 547 | Antiarrhythmic Drugs:. PACE - Pacing and Clinical Electrophysiology, 2003, 26, 2340-2348. | 0.5 | 5 |
| 548 | Modulation of drug block of the cardiac potassium channel KCNA5 by the drug transporters OCTN1 and MDR1. British Journal of Pharmacology, 2010, 161, 1023-1033. | 2.7 | 5 |
| 549 | Genome-Wide Assessment for Genetic Variants Associated with Ventricular Dysfunction after Primary Coronary Artery Bypass Graft Surgery. PLoS ONE, 2011, 6, e24593. | 1.1 | 5 |
| 550 | Ethical and practical challenges to studying patients who opt out of large-scale biorepository research. Journal of the American Medical Informatics Association: JAMIA, 2013, 20, e221-e225. | 2.2 | 5 |
| 551 | Size matters: How population size influences genotypeâ€“phenotype association studies in anonymized data. Journal of Biomedical Informatics, 2014, 52, 243-250. | 2.5 | 5 |
| 552 | Long QT Syndrome and Potentially Pathogenic Genetic Variantsâ€”In Reply. JAMA - Journal of the American Medical Association, 2016, 315, 2467. | 3.8 | 5 |
| 553 | Fundamental Cardiovascular Research: Returns on Societal Investment: A Scientific Statement From the American Heart Association. Circulation Research, 2017, 121, e2-e8. | 2.0 | 5 |
| 554 | Association of genetic variants previously implicated in coronary artery disease with age at onset of coronary artery disease requiring revascularizations. PLoS ONE, 2019, 14, e0211690. | 1.1 | 5 |
| 555 | Genomic Medicine Year in Review: 2020. American Journal of Human Genetics, 2020, 107, 1007-1010. | 2.6 | 5 |
| 556 | High-throughput framework forÂgenetic analyses of adverse drug reactions using electronic health records. PLoS Genetics, 2021, 17, e1009593. | 1.5 | 5 |
| 557 | Management of Congenital Long-QT Syndrome: Commentary From the Experts. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e009726. | 2.1 | 5 |
| 558 | Frequency of benign neutropenia among Black versus White individuals undergoing a bone marrow assessment. Journal of Cellular and Molecular Medicine, 2022, 26, 3628-3635. | 1.6 | 5 |

| # | Article | IF | Citations |
|---|---|---|---|
| 559 | Polygenic risk score for ACE-inhibitor-associated cough based on the discovery of new genetic loci. European Heart Journal, 2022, 43, 4707-4718. | 1.0 | 5 |
| 560 | A common polymorphism in KCNH2 (HERG) eliminates gender differences in drug-induced QT prolongation. Heart Rhythm, 2005, 2, S145. | 0.3 | 4 |
| 561 | P1-84. Heart Rhythm, 2006, 3, S135-S136. | 0.3 | 4 |
| 562 | Personalized medicine to treat arrhythmias. Current Opinion in Pharmacology, 2014, 15, 61-67. | 1.7 | 4 |
| 563 | The Brugada ECG and Schizophrenia. Circulation: Arrhythmia and Electrophysiology, 2014, 7, 365-367. | 2.1 | 4 |
| 564 | Exploiting ion channel structure to assess rare variant pathogenicity. Heart Rhythm, 2018, 15, 890-894. | 0.3 | 4 |
| 565 | Association of Genetic Risk of Obesity with Postoperative Complications Using Mendelian Randomization. World Journal of Surgery, 2020, 44, 84-94. | 0.8 | 4 |
| 566 | Atrial Fibrillation Is a Complex Trait. Circulation Research, 2020, 127, 244-246. | 2.0 | 4 |
| 567 | Genetic Testing for Early Onset Atrial Arrhythmias Changes Clinical Management. JACC: Clinical Electrophysiology, 2021, 7, 410-412. | 1.3 | 4 |
| 568 | 2-Hydroxybenzylamine (2-HOBA) to prevent early recurrence of atrial fibrillation after catheter ablation: protocol for a randomized controlled trial including detection of AF using a wearable device. Trials, 2021, 22, 576. | 0.7 | 4 |
| 569 | Antiarrhythmic Drugs. , 2007, , 2085-2102. | | 4 |
| 570 | Integrating EMR-Linked and In Vivo Functional Genetic Data to Identify New Genotype-Phenotype Associations. PLoS ONE, 2014, 9, e100322. | 1.1 | 4 |
| 571 | Genomic medicine year in review: 2021. American Journal of Human Genetics, 2021, 108, 2210-2214. | 2.6 | 4 |
| 572 | Uterine fibroid polygenic risk score (PRS) associates and predicts risk for uterine fibroid. Human Genetics, 2022, 141, 1739-1748. | 1.8 | 4 |
| 573 | A research agenda to support the development and implementation of genomics-based clinical informatics tools and resources. Journal of the American Medical Informatics Association: JAMIA, 2022, 29, 1342-1349. | 2.2 | 4 |
| 574 | Antiarrhythmic Therapy: Clinical Pharmacology Update. Journal of Clinical Pharmacology, 1984, 24, 295-305. | 1.0 | 3 |
| 575 | Antiarrhythmic drugs. Postgraduate Medicine, 1985, 78, 28-37. | 0.9 | 3 |
| 576 | Antiarrhythmic drugs: Past, present and future. Heart Rhythm, 2004, 1, C57-C66. | 0.3 | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 577 | Probing the arrhythmogenic substrate. Heart Rhythm, 2006, 3, 779-780. | 0.3 | 3 |
| 578 | Growing Pains in Cardiovascular Genetics. Circulation, 2018, 138, 1206-1209. | 1.6 | 3 |
| 579 | Loperamide Induced Recurrent Torsades de Pointes: A Case Report. Journal of Pharmacy Practice, 2022, 35, 791-795. | 0.5 | 3 |
| 580 | Recurrent Pregnancy Loss and Concealed Longâ€QT Syndrome. Journal of the American Heart Association, 2021, 10, e021236. | 1.6 | 3 |
| 581 | Abstract 4099: Genetic and Clinical Predictors of Response to Rate Control Therapy in Patients with Atrial Fibrillation. Circulation, 2008, 118, . | 1.6 | 3 |
| 582 | Improved high-performance liquid chromatographic assay for encainide and its metabolites in human body fluids. Biomedical Applications, 1989, 490, 165-174. | 1.7 | 2 |
| 583 | Angiotensin II Facilitates Tricyclic Antidepressant-Induced Changes in QRS-Duration in the Rat. Journal of Toxicology: Clinical Toxicology, 1992, 30, 83-98. | 1.5 | 2 |
| 584 | Recent Advances in the Long QT Syndrome. Journal of Interventional Cardiac Electrophysiology, 1997, 1, 262-263. | 0.9 | 2 |
| 585 | Principles in Pharmacogenetics. Epilepsia, 2001, 42, 44-48. | 2.6 | 2 |
| 586 | Drug-Induced Sudden Death. , 0, , 177-188. | | 2 |
| 587 | When should QT be measured? Summer solstice or Christmas Eve?. Heart Rhythm, 2007, 4, 282-283. | 0.3 | 2 |
| 588 | Genetics of Atherosclerosis. , 0, , 151-166. | | 2 |
| 589 | Genetic Testing in Subjects With No Clinical Abnormality. Journal of the American College of Cardiology, 2011, 57, 60-62. | 1.2 | 2 |
| 590 | Commotio cordis due to high-velocity projectile ejected from an industrial lawnmower. HeartRhythm Case Reports, 2015, 1, 172-175. | 0.2 | 2 |
| 591 | Finding a Needle in a QT Interval Big Data Haystack. Journal of the American College of Cardiology, 2016, 68, 1765-1768. | 1.2 | 2 |
| 592 | Arrhythmia genetics: Not dark and lite, but 50 shades of gray. Heart Rhythm, 2018, 15, 1231-1232. | 0.3 | 2 |
| 593 | The Case for Expanding the FDA Box Warning on Clopidogrel to CYP2C19 Intermediate Metabolizers. Clinical Pharmacology and Therapeutics, 2021, 110, 860-862. | 2.3 | 2 |
| 594 | Pleiotropy of systemic lupus erythematosus risk alleles and cardiometabolic disorders: A phenome-wide association study and inverse-variance weighted meta-analysis. Lupus, 2021, 30, 1264-1272. | 0.8 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 595 | Machine Learning Challenges in Pharmacogenomic Research. Clinical Pharmacology and Therapeutics, 2021, 110, 552-554. | 2.3 | 2 |
| 596 | A comparative study of different methods for automatic identification of clopidogrel-induced bleedings in electronic health records. AMIA Summits on Translational Science Proceedings, 2017, 2017, 185-192. | 0.4 | 2 |
| 597 | Veratridine Can Bind to a Site at the Mouth of the Channel Pore at Human Cardiac Sodium Channel NaV1.5. International Journal of Molecular Sciences, 2022, 23, 2225. | 1.8 | 2 |
| 598 | Intravenous 3-Methoxy-O-Desmethyl-Encainide in Reentrant Supraventricular Tachycardia: A Randomized Double-Blind Placebo-Controlled Trial in Patients Undergoing EP Study. PACE - Pacing and Clinical Electrophysiology, 1991, 14, 1343-1350. | 0.5 | 1 |
| 599 | Prospective pharmacokinetically based development of effective infusion regimens for ACCâ€“9358, a new antiarrhythmic drug. Clinical Pharmacology and Therapeutics, 1991, 49, 314-321. | 2.3 | 1 |
| 600 | An Overview of Contemporary Approaches to Antiarrhythmic Therapy. Japanese Circulation Journal, 1999, 63, 655-658. | 1.0 | 1 |
| 601 | Impact of recent molecular studies on evaluation of ventricular arrhythmias. , 2000, 4, 7-16. | | 1 |
| 602 | Delayed Activation and Retrograde Propagation in Cardiac Muscle: Implication of Virtual Electrode Effects. Annals of Biomedical Engineering, 2000, 28, 1318-1325. | 1.3 | 1 |
| 603 | Blunted verp response to isoproterenol in mink (KCNE1) knockout mice. Heart Rhythm, 2005, 2, S34. | 0.3 | 1 |
| 604 | Genetics and Genomics of Dilated Cardiomyopathy. , 0, , 118-135. | | 1 |
| 605 | Hypertrophic Cardiomyopathy and other Forms of Hypertrophy. , 0, , 96-117. | | 1 |
| 606 | Toxicology and Genetics of Adverse Drug Events. , 2009, , 339-344. | | 1 |
| 607 | Implementing Genomic Medicine in the Clinic. Obstetrical and Gynecological Survey, 2013, 68, 621-623. | 0.2 | 1 |
| 608 | Pharmacogenetic Implementation Lessons From the â€œReal Worldâ€• Clinical Pharmacology and Therapeutics, 2017, 102, 25-27. | 2.3 | 1 |
| 609 | Adverse Drug Events. , 2017, , 389-396. | | 1 |
| 610 | Reply to Ward and Colleaguesâ€™ Comment on â€œUsing Human Experiments of Nature to Predict Drug Safety Issues: An Example with PCSK9 Inhibitorsâ€• Drug Safety, 2018, 41, 1101-1101. | 1.4 | 1 |
| 611 | My Cousin Also Has Atrial Fibrillation. JACC: Clinical Electrophysiology, 2019, 5, 501-503. | 1.3 | 1 |
| 612 | Genome-Wide Association Study Identifies Variation in ABO As Risk Factor for Platelet Reactivity in Heparin-Induced Thrombocytopenia. Blood, 2020, 136, 38-39. | 0.6 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 613 | Glutamate Receptor Polymorphisms Contribute to Glucocorticoid-Associated Osteonecrosis. Blood, 2014, 124, 367-367. | 0.6 | 1 |
| 614 | Family Screening After Sudden Death in a Population-Based Study of Children. Pediatrics, 2022, 149, . | 1.0 | 1 |
| 615 | Genetic Determinants of Body Mass Index and Fasting Glucose Are Mediators of Grade 1 Diastolic Dysfunction. Journal of the American Heart Association, 2022, 11, . | 1.6 | 1 |
| 616 | Ventricular Arrhythmias and Sudden Death. , 0, , 80-95. | | 0 |
| 617 | Abolition of ventricular arrhythmias during chronic oral therapy with encainide in man. American Journal of Cardiology, 1980, 45, 451. | 0.7 | 0 |
| 618 | Suppression of complex ventricular arrhythmias by timolol. American Journal of Cardiology, 1982, 49, 1018. | 0.7 | 0 |
| 619 | Reply to Goldman. Biophysical Journal, 1991, 60, 522. | 0.2 | 0 |
| 620 | Editorial: Who Needs a New Journal?. Journal of Interventional Cardiac Electrophysiology, 1997, 1, 7-7. | 0.9 | 0 |
| 621 | QT shortening with exercise in normals: Terminal repolarization does not shorten with exercise. Heart Rhythm, 2005, 2, S223. | 0.3 | 0 |
| 622 | Intracellular Sodium Overload: A System Biology Problem with Implications for Drug Target Identification. Journal of Cardiovascular Electrophysiology, 2006, 17, S149-S150. | 0.8 | 0 |
| 623 | A Shock in Time. Clinical Journal of Sport Medicine, 2007, 17, 497-499. | 0.9 | 0 |
| 624 | Response to Letter Regarding Article, â€œCardiac Sodium Channel ( SCN5A ) Variants Associated with Atrial Fibrillationâ€• Circulation, 2008, 118, . | 1.6 | 0 |
| 625 | Genetic Testing: Moving to the Bedsideâ€”When and How?. , 0, , 47-64. | | 0 |
| 626 | A Primer in Statistical Methods in Genetics. , 0, , 20-32. | | 0 |
| 627 | Stroke Genomics. , 0, , 177-192. | | 0 |
| 628 | Genetic Determinants of Arterial Thrombosis. , 0, , 193-210. | | 0 |
| 629 | Case Study: Warfarin Pharmacogenetics from Single to Multiple Genes. , 2009, , 231-247. | | 0 |
| 630 | Author Disclosure Table. , 0, , 261-265. | | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 631 | The Role of Ethnicity in Managing Cardiovascular Patients. , 0, , 33-46. | | 0 |
| 632 | Candidate Gene and Genome-Wide Association Studies. , 0, , 1-19. | | 0 |
| 633 | Arrhythmogenic Right Ventricular Cardiomyopathy. , 0, , 136-150. | | 0 |
| 634 | Genomics and Atrial Arrhythmias. , 0, , 65-79. | | 0 |
| 635 | Symptomatic Response to Antiarrhythmic Drug Therapy is Modulated by a Common Single Nucleotide Polymorphism in Atrial Fibrillation. Heart Rhythm, 2010, 7, 1721-1722. | 0.3 | 0 |
| 636 | Response to Numann and Gibson. Circulation Research, 2012, 111, . | 2.0 | 0 |
| 637 | Pharmacogenomics of Cardiac Arrhythmias. , 2014, , 541-547. | | 0 |
| 638 | Atrial Fibrillation Genomics. Journal of the American College of Cardiology, 2014, 63, 1211-1213. | 1.2 | 0 |
| 639 | Partial Duplication and Poly(A) Insertion in KCNQ1 Not Detected by Next-Generation Sequencing in Jervell and Langeâ€“Nielsen Syndrome. Circulation: Arrhythmia and Electrophysiology, 2016, 9, . | 2.1 | 0 |
| 640 | Reprint of Editorial Commentary: Genomics and drug discovery: The next frontier in precision medicine. Trends in Cardiovascular Medicine, 2017, 27, 360-362. | 2.3 | 0 |
| 641 | Editorial Commentary: Genomics and drug discovery: The next frontier in precision medicine. Trends in Cardiovascular Medicine, 2017, 27, 203-206. | 2.3 | 0 |
| 642 | Arrhythmia Genomics. , 2018, , 179-196. | | 0 |
| 643 | Pharmacogenomics of Cardiac Arrhythmias. , 2018, , 525-530. | | 0 |
| 644 | A High-Throughput Genetic Analysis of Common Drug Allergy Labels Using Data from a Large Biobank. Journal of Allergy and Clinical Immunology, 2018, 141, AB399. | 1.5 | 0 |
| 645 | John A. Oates: A Founding Father of Clinical Pharmacology. Clinical Pharmacology and Therapeutics, 2019, 106, 1155-1157. | 2.3 | 0 |
| 646 | Response by Salem et al to Letter Regarding Article, â€œAndrogenic Effects on Ventricular Repolarization: A Translational Study From the International Pharmacovigilance Database to iPSC-Cardiomyocytesâ€• Circulation, 2020, 141, e63-e64. | 1.6 | 0 |
| 647 | B-PO04-136 RELATIONSHIP BETWEEN ATRIAL FIBRILLATION AND DECLINING RENAL FUNCTION. Heart Rhythm, 2021, 18, S335. | 0.3 | 0 |
| 648 | B-PO03-017 ROLE OF KV11.1 MISTRAFFICKING IN HIGHLY PENETRANT KCNQ1 VARIANTS. Heart Rhythm, 2021, 18, S195. | 0.3 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 649 | Incessant atrial and ventricular tachycardias associated with an SCN5A mutation. HeartRhythm Case Reports, 2021, 7, 806-811. | 0.2 | 0 |
| 650 | Heart failure clinical care analysis uncovers risk reduction opportunities for preserved ejection fraction subtype. Scientific Reports, 2021, 11, 18618. | 1.6 | 0 |
| 651 | Pharmacogenetics and Cardiac Ion Channels. Drugs and the Pharmaceutical Sciences, 2005, , 207-220. | 0.1 | 0 |
| 652 | RHYTHM DISORDERS. , 2009, , 367-387. | | 0 |
| 653 | Genome-Wide Association Study (GWAS) Of Venous Thromboembolism (VTE) In African-Americans From The Electronic Medical Records & Genomics (eMERGE) Networkm. Blood, 2013, 122, 458-458. | 0.6 | 0 |
| 654 | Genomics of Cardiac Arrhythmias. Cardiovascular Medicine, 2017, , 27-36. | 0.0 | 0 |
| 655 | A Bayesian method to estimate variant-induced disease penetrance. , 2020, 16, e1008862. | | 0 |
| 656 | A Bayesian method to estimate variant-induced disease penetrance. , 2020, 16, e1008862. | | 0 |
| 657 | A Bayesian method to estimate variant-induced disease penetrance. , 2020, 16, e1008862. | | 0 |
| 658 | A Bayesian method to estimate variant-induced disease penetrance. , 2020, 16, e1008862. | | 0 |
| 659 | A Bayesian method to estimate variant-induced disease penetrance. , 2020, 16, e1008862. | | 0 |
| 660 | A Bayesian method to estimate variant-induced disease penetrance. , 2020, 16, e1008862. | | 0 |
| 661 | Pharmacogenetics and Pharmacogenomics. , 0, , 211-230. | | 0 |
| 662 | PO-691-03 FUNCTIONAL ASSAYS IDENTIFY SPLICE-ALTERING VARIANTS IN MENDELIAN CHANNELOPATHIES. Heart Rhythm, 2022, 19, S399. | 0.3 | 0 |